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Abstract 
Background/Aim: The innate immune system is a complex system which maintains 
a fine balance between homeostatic function and the inflammatory response. It has 
been demonstrated that a number of pathologies occur as a result of dysregulation of 
the immune system. Whilst classically associated with apoptosis, the Fas (CD95) 
signalling pathway has also been demonstrated to play a role in inflammation. 
Studies have demonstrated that Fas activation augments TLR4-mediated MyD88-
dependent cytokine production, whilst the Fas adapter protein FADD is required for 
RIG-I-induced IFNβ production. As a similar signalling pathway exists between 
RIG-I, TLR3 and the MyD88-independent of TLR4, we hypothesised that Fas 
activation may modulate both TLR3- and TLR4-induced cytokine production.  
Results: The dsRNA mimetic, poly I:C, induced IFNβ, IL-8, IL-10 and TNFα which 
were reduced by Fas activation. However, poly I:C-, poly A:U- and Sendai virus-
induced IP-10 production were augmented by Fas activation, demonstrating that this 
effect was not receptor specific. Overexpression studies demonstrated that the Fas 
adapter protein FADD inhibits TLR3-, RIG-I- and MDA5-induced IP-10 luciferase 
activation. Poly I:C-induced phosphorylation of p-38 and JNK MAPK was reduced 
by Fas activation, with overexpression studies demonstrating that FADD induces 
AP-1 luciferase activation. Point mutations in the AP-1 binding site also resulted in 
enhanced poly I:C-induced IP-10 production. LPS-induced IL-10, IL-12, IL-8 and 
TNFα production were enhanced by Fas activation. Fas activation reduced LPS-
induced IFNβ production. Absence of FADD using FADD-/- MEFs resulted in 
impaired IFNβ production compared to wild-type MEFs whilst overexpression 
studies demonstrated that FADD augments TLR4-, MyD88- and TRIF-induced IFNβ 
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luciferase activation. Overexpression studies also suggested that enhanced TLR4-
induced IFNβ production was independent of NFκB activation. 
Conclusion: Viral-induced IP-10 production is augmented by Fas activation which 
alleviates the repressive activity of FADD on the system, with Fas activation 
reducing phosphorylation of p-38 and JNK MAPKs. This reduces the activation of 
the transcription factor AP-1, thus alleviating the negative effect of AP-1 on the IP-
10 promoter, promoting IP-10 production. The Fas signalling pathway reduces LPS-
induced IFNβ production, whilst augmenting all other cytokines investigated, with 
our data demonstrating that FADD is required for TLR4-induced IFNβ production. 
Studies presented here demonstrate that the Fas signalling pathway can therefore 
modulate the immune response. Our data demonstrates that this modulatory effect is 
mediated by its adapter protein FADD, which tailors the immune response by acting 
as a molecular switch. This ensures the appropriate immune response is mounted, 
thus preventing an exacerbated immune response, therefore limiting collateral 
damage to the host following infection.  
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Chapter 1 
General Introduction  
2 
 
1.1.1 The Innate Immune System 
The innate immune system consists of physical barriers and phagocytic immune 
cells. It is the first line of defence of the host, providing protection against a myriad 
of infections. The innate immune system relies on the recognition of evolutionary 
conserved molecular patterns that are common and essential for survival of 
microbes, but are absent in the host. These are known as pathogen associated 
molecular patterns (PAMPs) (1). Recognition of these PAMPs occurs through the 
presence of germline-encoded pattern recognition receptors (PRRs) which are a vital 
component of the innate immune system (2). Whilst recognition of PAMPs by PRRs 
can result in cytokine production, phagocytosis by antigen presenting cells (APCs) 
such as dendritic cells and macrophages can also occur. The pathogenic antigen is 
then presented on the APC, which upon recognition by antigen specific naïve T 
lymphocytes, results in activation of the adaptive immune response.  
1.1.2 Innate immune cells 
Innate immune cells are diverse in nature and represent the first line of defence of 
the host. These cells express and utilise the PRRs to mount an immune response 
against pathogenic material in the early hours of infection (3). Phagocytic leukocytes 
are white blood cells which are generated from haematopoietic stem cells, 
differentiating into the various subsets depending on the colony stimulating factor to 
which they are exposed (4). Neutrophils are the predominant leukocyte present in the 
bloodstream, are both secretory and phagocytic cells and are the first cell type to 
arrive at the site of infection. Recent studies have demonstrated that neutrophils 
target both gram-positive and gram-negative bacteria by neutrophil extracellular 
traps (NETs) (5). Crosstalk between both neutrophils and macrophages also aids the 
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innate immune response, with neutrophils producing macrophage inflammatory 
protein-1α (MIP-1α) and MIP-1β, resulting in migration of macrophages to the site 
of infection (5). 
Macrophages are an essential component of the innate immune system, capable of 
multiple functions including phagocytosis and antigen presentation. They are formed 
as a result of migration of monocytes from the blood stream into various tissues, 
with the resultant macrophages adopting specific functions dependent on their 
location (6). The heterogeneous nature of macrophages can be observed when 
comparing macrophages from different locations. PRRs and scavenger receptors are 
highly expressed on alveolar macrophages present in the lungs (6), inducing the 
expression of inflammatory cytokines, inducing an immune response thus clearing 
the infection (7). As transmission of many pathogenic microorganisms occurs 
through exposure to infective airborne particles (8), this upregulation and production 
of cytokines is unsurprising, resulting in a heightened immune response towards 
pathogenic material.  
Macrophages present in the gut are constantly exposed to commensal bacteria; 
therefore, intestinal macrophages lack some innate immune receptors which are 
present on blood monocytes, therefore reducing their capacity to react to commensal 
bacteria. Whilst cytokine production by these macrophages is compromised, these 
macrophages still retain their phagocytic and bacteriocidal capacity (9), therefore 
allowing these cells to function in close proximity to commensal bacteria whilst 
recognising and mounting an immune response against pathogens.  
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1.2 Pattern Recognition Receptors 
A variety of PRRs exist, each designed to evoke a specific immune response targeted 
against specific invading pathogens. These include Toll-like Receptors (TLRs), 
Nuclear Oligodimerization Domain (NOD)-Like Receptors (NLRs), C-type Lectin 
(CLEC) receptors (CLRs) and retinoic acid-inducible gene-I (RIG-I) like Receptors 
(RLRs), which recognise a range of evolutionary conserved PAMPs. Secreted PRRs, 
such as collectins and ficolins trigger activation of the lectin pathway of the 
complement system, resulting in the opsonisation of micro-organisms (10). This 
allows phagocytosis to occur resulting in antigen expression by immune cells, 
activating the adaptive immune system (11). Recent studies have also demonstrated 
that the human caspases, caspase-4 and caspase-5, and the murine homolog caspase-
11 directly bind to lipopolysaccharide (LPS) (12-14), indicating that these can be 
added to the list of known PRRs (14). These PRRs are poised to mount a rapid 
immune response culminating in the production of chemokines and cytokines. 
1.2.1 Toll-like Receptors 
Macrophages express a number of different PRRs, a family of which are the TLRs. 
The protein Toll was first identified in the fruit fly Drosophilia melanogaster by 
Nüsslein-Volhard and Wieschaus (15). It was initially demonstrated that Toll was 
required for the development of the dorsal-ventral axis in Drosophilia (15). Further 
studies demonstrated that it also played a significant role in the prevention of 
microbial infections in Drosophilia, whereby an absence of Toll in these flies 
resulted in them being highly susceptible to fungal infection (16). This subsequently 
led to the discovery of its mammalian homolog, Toll-like receptor 4 (TLR4) (17). 
Prior to the discovery of Toll in the fruit fly Drosophilia melanogaster, the innate 
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immune system was seen as a rudimentary system with its sole purpose being 
activation of the adaptive immune system. However, with the identification of Toll 
and TLR4, research in this field has led to the discovery of a multitude of other 
TLRs and indeed, PRRs of the innate immune system. 
TLRs are a vital part of the innate immune system. To date, 13 mammalian TLRs 
have been identified, 10 of which are expressed in humans, each having homology to 
the interleukin-1 receptor (IL-1R) (18). They are defined as type 1 transmembrane 
glycoproteins and along with members of the IL-1R family share a conserved stretch 
of ~200 amino acids in their cytoplasmic region known as the Toll/IL-1R (TIR) 
domain (19). This TIR domain is composed of three conserved boxes, formed from a 
central five stranded β-sheet surrounded by five α-helices, of which BB loops 
connect these secondary structures, connecting β-strand B with α-helix B (20). This 
BB loop contains within it a conserved proline residue which is present in all TLRs 
except that of TLR3, which contains an alanine residue at that site (21). 
Conservation of this proline residue induces LPS responsiveness. Substitution of 
proline to histidine induces resistance to endotoxin, as observed in C3H/HeJ mice  
The extracellular portion of TLRs contains Leucine-Rich-Repeats (LRRs) (22, 23) 
appearing in a xLxxLxLxx motif (2, 19). Recognition of the ligand by its cognate 
receptor induces activation of intracellular signalling cascades resulting in 
production of appropriate cytokines and chemokines (24).  
Ligands for all TLRs with the exception of TLR10 have now been elucidated (Table 
1.1).  
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Table 1.1 Intracellular location of each TLR with their known respective 
ligands and the origin of each ligand. 
 
Receptor Location Ligand Ligand origin 
TLR1 Cell surface multiple triacyl lipopeptides Bacteria 
TLR2 Cell surface 
multiple glycolipids, 
multiple lipoproteins, Heat 
Shock Protein (HSP)70 
zymosan, High Mobility 
Group Protein B1 
(HMGB1), Lipoteichoic 
acid, haemaglutinin 
Bacteria 
Bacteria 
Host 
Fungi 
TLR3 
Cell 
compartment 
double-stranded RNA 
(dsRNA) 
Viruses 
TLR4 Cell surface 
lipopolysaccharide (LPS), 
several HSPs, 
fibrinogen, heparin sulfate, 
fibronectin, hyaluronic acid, 
HMGB1, F-protein (RSV), 
lipotechoic acid 
Gram-negative 
bacteria 
Bacterial and host 
cells 
Host 
TLR5 Cell surface Flagellin Bacteria 
TLR6 Cell surface 
multiple diacyl lipopeptides, 
lipoteichoic acid, zymosan 
Mycoplasma 
TLR7 
Cell 
compartment 
Single stranded RNA 
(ssRNA) 
RNA Viruses 
TLR8 
Cell 
compartment 
Single stranded RNA 
(ssRNA) 
RNA Viruses 
TLR9 
Cell 
compartment 
unmethylated CpG 
oligodeoxynucleotide DNA 
Bacteria, DNA 
Viruses 
TLR10 Cell surface ? ? 
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TLRs are present both on the plasma membrane, as well as endosomally, poising 
them for appropriate PAMP recognition and response (24). TLRs 1, 2, 4, 5 and 6 are 
located on the plasma membrane, and predominantly recognise microbial cell wall 
components. Whilst TLR1 and 2 are capable of recognising bacterial lipoproteins, 
TLR2 requires dimerization with TLR1 or TLR6 in order to mediate an appropriate 
immune response (18). TLR5 recognises flagellin which is present in gram-positive 
and gram-negative bacterial flagella (25). Recognition of LPS by LPS Binding 
protein (LBP) facilitates the interaction between LPS and CD14 (26, 27), resulting in 
shuttling of LPS to the lymphocyte antigen 96 (MD2)-TLR4 complex (28, 29). 
TLR4 then homodimerizes, resulting in the recruitment of its adapter proteins. This 
induces the activation of downstream signalling components and eventual induction 
of cytokines (19). While well defined as a receptor of LPS, a component of gram-
negative cell walled bacteria, studies have now demonstrated that TLR4 can also 
recognise viral particles, as well as gram-positive bacteria (18).  
Endosomally located TLRs primarily detect nucleic acids, in particular by-products 
of viral reproduction (24). TLR3, along with TLR7, 8 and 9 localizes to the 
endosome, with TLR3 recognising double-stranded RNA (dsRNA), while both 
TLR7 and 8 recognise single-stranded RNA (ssRNA). TLR9 recognises 
unmethylated CpG Oligodeoxynucleotide DNA from both DNA viruses and 
bacteria. TLR11 has been reported to recognize uropathogenic E. coli (30) and a 
profilin-like protein from Toxoplasma gondii (31). TLR10 has also been shown to be 
located intracellularly and whilst it has been shown to recognise the micro-organism 
Listeria monocytogenes (32), its exact ligand has yet to be elucidated.  
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As TLR3 and TLR4 are the main focus of this work, they will be described in more 
detail. 
1.2.2 Toll-like Receptor 4 Signalling Pathway 
Following recognition of LPS, recruitment of the adapter protein Mal to TLR4 
occurs, resulting in the recruitment of Myeloid differentiation adapter protein 
(MyD88) (33). MyD88 can then recruit the IL-1 receptor kinase-4 (IRAK-4) through 
DD-DD interactions, subsequently recruiting IRAK-1. Phosphorylation and 
ubiquitylation of IRAK-1 then results, allowing for association between IRAK-1 and 
TNFR-Associated Factor (TRAF)6 to occur. This induces both oligomerization and 
polyubiquitination of TRAF6. The E3 ubiquitin ligase Pellino1 also induces 
ubiquitylation of TRAF6. Following both auto-ubiquitylation and ubiquitiylation of 
TRAF6, TRAF6, present in the IRAK-1 complex, becomes activated and 
subsequently dissociates from the receptor, allowing two TAK-binding proteins, 
TAB2 and TAB3 to associate with TGF-β-activated kinase (TAK1). This induces 
phosphorylation of inhibitor of kappa B Kinase-β (IKKβ), resulting in recruitment of 
TAK1. Inhibitory κB (IκB) bound in a complex with Nuclear Factor κ B (NFκB) is 
then degraded, resulting in translocation of NFκB to the nucleus, thus inducing 
production of inflammatory cytokines and chemokines (34). Similarly, TAK1 also 
induces activation of c-Jun N-terminal Kinase (JNK), extracellular signal related 
kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinases (MAPKs). This 
induces activation of the transcription factor activator protein-1 (AP-1), resulting in 
production of cytokines and chemokines. Additional proteins not detailed here are 
involved in this pathway as outlined in figure 1.1 (35). 
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Figure 1.1: Signalling pathway of Toll like receptor 4  
 
Following ligand recognition, TLR4 initiates a downstream signalling cascade using 
the adapter molecules Mal and MyD88, resulting in activation of NFκB and the 
MAPKs. This induces the production of inflammatory cytokines. TLR4, when 
trafficked to the endosome, recruits the adapter proteins TRAM and TRIF, resulting 
in the activation of IRF3, inducing the production of inflammatory cytokines. 
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Following activation of the MyD88 dependent pathway, it is thought that 
internalization of the receptor occurs in a clathrin and dynamin dependent manner, 
allowing activation of the MyD88 independent pathway to occur (36). This pathway 
is generally referred to as a late response pathway. It is thought that TLR4, now 
present in endosomes is recognised by TRIF related adapter molecule (TRAM). 
TRAM binds to the TIR domain in TLR4 once bound to MyD88. TRAM now binds 
to TRIF. TRIF then recruits Receptor Interacting Protein 1 (RIP1) through RIP 
homotypic interaction motif (RHIM) interactions, which can then complex with 
TNFR1-associated death domain protein (TRADD), which mediates downstream 
activation of signalling molecules, resulting in TRIF-induced NFκB activation and 
cytokine production (37). Whilst it is unclear whether Pellino-1 acts directly on RIP1 
(38), it has been demonstrated that phosphorylation of Pellino-1 by the TBK1-IKKε 
complex (39) induces polyubiquitylation of RIP1, resulting in recruitment of TAK1, 
and TAB1/2 and NFκB essential modulator (NEMO), resulting in the activation of 
downstream transcription factors such as NFκB and AP-1 (Activator-protein-1), 
resulting in cytokine production. TRIF also recruits the signalling intermediate 
TRAF-3 which can interact with TRAF family member-associated NFκB activator 
(TANK), TANK binding kinase 1 (TBK-1) and also IKKε (IKKi). Dimerization and 
translocation of the Interferon regulatory factor 3 (IRF3) to the nucleus then results 
from interaction of TBK1 and IKKε, inducing the production of interferons (figure 
1.1) (36). 
The TLR4 signalling pathway is tightly regulated, with upwards of 35 regulatory 
proteins identified to date (40-42). IRAK-M is an inactive kinase which binds to and 
prevents IRAK4 and IRAK1 association with MyD88. As a result, the MyD88 
signalling pathway is interrupted thus limiting NFκB activation (43). A20 is a 
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ubiquitin-modifying enzyme with deubiquitination of RIP1 by A20 preventing the 
activity of RIP1, and thus, any activation of downstream signalling intermediates 
again limiting NFκB activation (44). Sterile α- and armadillo-motif-containing 
protein (SARM) has been shown to limit TLR4-induced cytokine production (45). 
Whilst studies have shown that SARM and TRIF can directly interact, it has been 
demonstrated that SARM mediates its negative regulatory effect by inhibiting 
MAPK activation, thus limiting activation of NFκB, reducing the production of 
cytokines (46). 
1.2.3 Toll-like Receptor 3 Signalling pathway 
TLR3 recognises dsRNA from viruses such as respiratory syncytial virus (RSV) and 
rotavirus and therefore it predominantly induces production of anti-viral cytokines 
such as interferon-β (IFNβ). It is capable however, of inducing interleukin 
production through activation of NFκB. In the resting state, TLR3 is found within 
the endosome compartment (47, 48). This may be a mechanism preventing activation 
of TLR3 by self-nucleic acids (49). While TLR3 can be expressed on the cell 
surface, for example on human fibroblasts, it has been suggested that expression on 
the cell surface may be transient as viral infection of A549 lung epithelial cells with 
RSV led to detection of cell surface TLR3 (50). In contrast, TLR3 cell surface 
expression was not detected in A549 cells devoid of infection with RSV (50). 
TLR3 signalling utilises the adapter molecule TRIF for signal transduction. Upon 
recognition of dsRNA, TLR3 becomes phosphorylated at two tyrosine residues 
present in its cytoplasmic tail (51). TRIF is recruited via TIR-TIR interaction to 
TLR3 (52), which can then associate with TRAF-3 and TRAF-6 through TRAF-
binding motifs contained within its N-terminal portion (24, 53). Recruitment of 
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TRAF3 then results in activation of TBK-1 and the IκB kinases IKKε/i which 
induces phosphorylation and subsequent activation and dimerization of IRF-3 and 
IRF-7 which migrate to the nucleus. This results in an anti-viral response by 
induction of type-1 interferons (figure 1.2) (24).  
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Figure 1.2: Signalling pathway of Toll like receptor 3 
Following ligand recognition, TLR3 initiates the activation of a downstream 
signalling cascade using the adapter TRIF which initiates downstream activation of 
TRAF3 and subsequently TBK1 which results in activation of the transcription 
factor IRF3, inducing the production of anti-viral interferon genes. TRIF also 
recruits RIP1 through RHIM interactions, which mediates activation of TAK1, 
initiating the activation of the downstream signalling cascade, resulting in activation 
of NFκB. This induces the production of inflammatory cytokines. 
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Whilst the adapter proteins MyD88 and Mal are not required for TLR3-induced 
signalling, recent studies have demonstrated that these proteins may act as negative 
regulators of the TLR3 signalling pathway, thus limiting IFNβ production (54, 55). 
They demonstrated that MyD88
-/- macrophages had enhanced IFNβ production 
compared with wild-type macrophages following poly I:C stimulation, with 
overexpression of MyD88 observed to inhibit IKKε activity, limiting IFNβ 
production (54). Similarly, poly I:C-induced production of IFNβ by Mal-/- Bone 
marrow-derived macrophages (BMDMs) was also enhanced, with Mal inhibiting the 
activity of Interferon Regulatory Factor (IRF)7 (55). 
In addition to the TIR domain, TRIF also contains the RHIM which facilitates 
interaction with RIP1, required for TLR3 induced NFκB activation (37). Upon 
phosphorylation of Pellino-1 by the TBK1-IKKε complex, RIP1, held in a complex 
with TRADD, undergoes Pellino-1 mediated ubiquitylation (39). TAK1 mediates 
downstream TLR3-induced activation of NFκB by both TRAF6 and RIP1 (56). Both 
TRAF6 and RIP1 utilise the same downstream molecules, IKKα, IKKβ and NEMO, 
collectively known as the IKK complex which induce the phosphorylation of IκB, 
thus allowing the activation of the transcription factor NFκB resulting in the 
production of inflammatory cytokines and chemokines (figure 1.2) (57).  
 
  
15 
 
1.2.4 RIG-I like Receptors (RLRs) 
RLRs are located intracellularly and recognise viral components present in the 
cytoplasm of the cell. This family comprises of RIG-I, Melanoma Differentiation-
associated Antigen 5 (MDA-5) and Laboratory of Genetics and Physiology 2 
(LGP2), all composed from three DExD/H box helicases which are essential for viral 
recognition (58, 59).  
RIG-I and MDA5 have a number of similarities in their structures and are organised 
into three distinct domains: an N-terminal region which has sequential caspase 
activation and recruitment domains (CARDs), a central DExD/H box RNA helicase 
domain, and a C-terminal repressor domain (RD) which is enclosed within the C-
terminal domain (CTD) present only in RIG-I (figure 1.3a) (59). MDA5 recognises 
long dsRNA, while RIG-I recognises both short dsRNA molecules and ssRNA 
which are phosphorylated at the 5’ end (60, 61). RIG-I and MDA5 associate with 
dsRNA through the helicase domain (62), as unwinding of dsRNA occurs through an 
ATPase dependent process (63). Once the dsRNA binds to the helicase domain of 
the RIG-I molecule, a conformational change occurs in RIG-I (57), which releases 
the CARD domain enabling interaction with interferon-β promoter stimulator 1 (IPS-
1, also known as mitochondrial anti-viral signalling protein (MAVS), virus-induced 
signalling adaptor (VISA) and CARD adaptor inducing IFNβ (CARDIF)) through 
CARD-CARD interactions (64).  
Both RIG-I and MDA5 share common signalling intermediates as they both activate 
the adapter protein IPS-1 (65, 66). IPS-1 interacts with RIG-I and MDA5 through 
CARD-like domains present in the N-terminal, IPS-1 recruiting the downstream 
signalling components Fas-associated protein with death domain (FADD) and RIP1 
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through the C-terminal effector domain (65). TRADD has also been implicated in 
RLR signalling. It has been demonstrated that IPS-1 recruits TRADD which then 
forms a complex with both FADD and RIP1 through death domain interactions (DD-
DD) (59, 67). Following ubiquitination of RIP1, NEMO is recruited, acting as a 
scaffold for both IKKα and IKKβ thus leading to NFκB activation (67). RLR 
activation also results in interaction of the RLR adapter protein IPS-1 with TRAF3 
through TRAF-interacting motif (TIM) (59, 68). Recruitment of TRAF3 results in 
the recruitment of both TBK-1 and IKKε. This results in phosphorylation and 
activation of both IRF3 and IRF7, resulting in the production of type-1 IFNs (figure 
1.3b) (68).  
The role of LGP2 in anti-viral signalling is not well defined. However, it is thought 
that RIG-I and MDA5 are regulated by LGP2 (69) potentially by sequestering 
dsRNA which prevents LGP2 from binding to RIG-I and/or MDA5 through the 
action of its repressor domain (RD) (68, 70). 
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Figure 1.3: Structure representation and signalling pathway of RIG-I and 
MDA5 
 
(a) RIG-I and MDA5 consists of two CARD domains; a DEAD helicase and a C-
terminal domain that encodes the repressor domain. (b) Upon ligand recognition, 
RIG-I and MDA5 recruit the adapter protein IPS-1. TRAF3 mediates activation of 
TBK1, resulting in the activation of the transcription factors, IRF3/7. IPS-1 also 
interacts with RIP-1, resulting in activation of a downstream signalling cascade, 
culminating in activation of the transcription factor, NFκB. 
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1.2.5 NOD-like Receptors 
NLRs are intracellular cytosolic sensors, involved primarily in bacterial recognition. 
They are composed of a tripartite structure, similar to that of plant R-proteins. They 
consist of an N-terminal effector binding region containing protein-protein 
interaction domains such as CARD, pyrin (PYD) and baculovirus inhibitor repeat 
(BIR) domains, an intermediary nucleotide binding and oligomerization domain 
(NOD) and an array of C-terminal LRR motifs which detect microbial PAMPs and 
modulate NLR activity (71). Spontaneous activation of NLR proteins is thought to 
be prevented by the LRRs in the C terminus folding back onto the NOD domain (72, 
73). To date, 23 NLR proteins exist in humans, with 34 in mice (74). NOD1 and 
NOD2 are well characterised members of this family which recognise peptidoglycan 
components of bacterial cell walls (figure 1.4a). NOD1 recognises γ-D-glutamyl-
meso-diaminopimlic acid, present in all Gram-negative but only some Gram-positive 
bacteria, while NOD2 recognises muramyl dipeptide, present in both Gram-positive 
and Gram-negative bacteria (75). Upon activation of these receptors, conformational 
changes occur causing the receptors to self-oligomerise. This in turn exposes the 
effector domains, recruiting and activating a downstream kinase of the NOD 
signalling cascade, RICK (RIP2), a serine-threonine kinase specifically required for 
NOD1/2 signalling. This is required for NFκB and MAPK activation (76, 77).  
Several distinct members of the NLR family of receptors, including NLRP3 and 
NLRP4, have been described (figure 1.4b). These NLR family members can form a 
high molecular weight complex termed the inflammasome upon recognition of 
PAMPs as well as Damage Associated Molecular Patterns (DAMPs) (78, 79). Upon 
activation, oligomerization of these NLRs occur, resulting in the recruitment of 
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apoptosis-associated speck-like protein containing a CARD (ASC) through PYD-
PYD interactions, resulting in the formation of multimers of ASC dimers. ASC then 
recruits procaspase-1 by CARD-CARD interactions, inducing self-cleavage of 
procaspase-1, resulting in its activation. This in turn activates both pro-IL-1β and 
pro-IL-18 (78-80). This pathway is termed the canonical pathway as it does not 
require additional co-factors for processing of IL-1β. TLR4-induced IFNβ 
production is however required for processing of IL-1β in the NLRP3 
inflammasome, with IFNβ activating caspase-11 thereby resulting in the activation 
of caspase-1 and the production of IL-1β and IL-18 (figure 1.4c) (78).   
Inflammasome formation can also induce pyroptotic cell death as a result of caspase-
1 activation which shares features with both apoptosis and necrosis, inducing an 
inflammatory response (78). 
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Figure 1.4 Structure of the NLRs NOD1, NOD2, NLRC4 and NLRP3 and 
depiction of inflammasome formation 
(a) NOD1 and NOD2 are composed of three domains: a carboxy-terminal LRR 
domain, a central NOD domain, and an amino-terminal domain composed of a 
CARD. (b) NLCR4 and NLRP3 are composed of a carboxy-terminal LRR, a NOD 
domain, and either a CARD domain or PYD domain respectively. (c) Upon 
activation, oligomerization of NLRs, recruiting ASC. This results in formation of the 
inflammasome, resulting in the activation of caspase-1 and processing of IL-18 
(Lechtenberg et al. (80)). 
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1.2.6 C-type Lectins (CLRs) 
CLRs are PRRs well characterised for their role in fungal recognition, recognising 
carbohydrate based moieties through at least one carbohydrate recognition domain 
(CRD) present on the receptor. Present as both transmembrane proteins and soluble 
proteins, to date, 17 groups exist within this family consisting of over 1,000 
members. They are distinguished from each other according to phylogeny and 
structure, with further subdivisions made based on the signalling potential of the 
CLR (81). Recent studies suggest however, that CLRs also recognise other 
pathogens such as bacteria and viruses (82-85). In terms of their role in bacterial 
infection, CLRs have been implicated in controlling M. tuberculosis (MTB) 
infection in vitro, however, in vivo studies have failed to replicate these findings (82, 
83).  
CLRs have also been implicated in viral infection in both a protective and 
detrimental manner. Activation of the CLR, DC-SIGN appears to exacerbate HIV 
infection by promoting viral survival, thus favouring transmission, infection and 
inflammation. This occurs as a result of modulating TLR-induced cytokine 
production and inducing accelerated dendritic cell (DC) apoptosis, dampening the 
maturation process of DCs in general, enhancing viral infection (84). Conversely, 
CLRs appear to have a protective role in the host against Herpes Simplex virus, 
whereby CLRs recognise dead and damaged cells, inducing activation of CD8
+
 T 
cells (85).  
Taken together, it is clear that PRRs in their entirety facilitate removal of invasive 
micro-organisms, both individually and in collaboration with each other, 
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demonstrating that the innate immune system is a diverse and complex entity in the 
host’s armoury against infection. 
1.3.1 The Fas Receptor 
Fas (CD95/APO-1) is expressed as a homotrimer (86, 87) by numerous cells 
throughout the body, including lymphoid immune cells as well as in the heart, 
kidney and liver (88-90). Fas was first identified as a death receptor as a result of the 
specific apoptotic ability of anti-Fas antibodies on tumour cells (91, 92). Fas is a 
45kDa type-1 transmembrane protein and is a member of the TNF receptor 
superfamily of death receptors, that also include TNFR1, TNFR2, DR3, TRAIL-R1 
(DR4) and TRAIL-R2 (DR5), which share  homology in their extracellular cysteine 
rich domains (93).  
The Fas gene is comprised of nine exons, separated by 8 introns. It consists of three 
cysteine-rich domains (CRDs), the hallmark of the TNFR superfamily, present in the 
N terminal region encoded by exons 1 through 5, a transmembrane domain encoded 
by exon 6, and the intracellular domain encoded by exons 7 through 9 which 
contains a death domain (DD) composed of 80 amino acids (94). This facilitates the 
interaction with the DD of its adapter protein, FADD (figure 1.5a).  
1.3.2 Fas Ligand 
Activation of Fas signalling occurs following binding of the Fas receptor by its 
ligand, Fas Ligand (FasL/CD95L). FasL is a 40kDa type II transmembrane protein 
(95) expressed on activated T cells, NK cells and cytotoxic T lymphocytes (96), as 
well as in immune privileged sites such as the eye, testis, ovary and placenta (97, 
98). The human FasL gene is composed of four exons. Interaction between Fas and 
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FasL is mediated by the specific receptor binding domain, present in the C terminal 
extracellular domain of FasL, which binds to the CRD of Fas. It is thought that the 
highly conserved proline residues contained within the N terminal intracellular 
domain of FasL, along with several potential tyrosine phosphorylation sites may 
influence FasL protein sorting to secretory lysosomes (96). Oligomerization of FasL 
is mediated by a self-assembly domain on FasL, whilst the function of the putative 
casein kinase I (CKI) motif has yet to be elucidated (figure 1.5b) (96). 
1.3.3 The Fas associated death domain containing protein (FADD) 
The FADD (Mort-1) gene is located on chromosome 11q13.3 in humans and 
chromosome 7 in mice and is organised into two exons, separated by a 2kb intron 
(99). Murine FADD shares 68% identity with that of human FADD (100). Within its 
structure, FADD contains two well conserved domains, the DD and the Death 
Effector Domain (DED), present in the C-terminal region in exon 2and in the N-
terminal region in exon 1 respectively (figure 1.5c) (99, 101).    
FADD is required for activation of the Fas signalling pathway. It has also been 
demonstrated that FADD is required for embryo development. Homozygous FADD 
mutant mice, generated by gene targeting in embryonic stem cells, did not survive in 
utero (102). Although FADD was detected in all tissues, with the expression of 
FADD concentrated in the brain, liver, developing vertebrae and myocardium, the 
requirement of FADD for embryo development is thought to be due to its role in the 
development of the ventricular myocardium (102).  
Through the presence of the DD, FADD can also interact with other members of the 
TNF family of death receptors through DD-DD interactions. FADD can interact with 
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the TNF-R1 signalling pathway through interaction with its adapter protein TRADD, 
inducing NFκB activation (103). Internalisation of the TNFR1 receptor results in 
dissociation of TRADD, which can now interact with FADD, resulting in apoptosis 
(103). FADD also interacts with both DR4 and DR5 through DD-DD interactions, 
resulting in both apoptosis (104, 105) and in activation of NFκB  (106).  
 
 
 
 
  
25 
 
 
Figure 1.5: Structure of Fas, FasL and FADD protein 
(a) Fas contains within its extracellular domain three cysteine-rich domains, a 
transmembrane domain, and a death domain contained within the intracellular 
domain in the N-terminus. (b) The C-terminal extracellular domain of FasL contains 
a specific receptor binding domain and self-assembly domain. FasL also contains a 
transmembrane domain. FasL contains a conserved proline rich domain and casein 
kinase I (CKI) within the N-terminal domain. (c) FADD contains an N-terminal 
DED domain and a C-terminal DD domain. 
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1.3.4 Apoptotic pathways of Fas 
Cell death can occur by apoptosis, autophagy, necrosis (107), and the more recently 
identified necroptosis (108). Apoptosis is a form of programmed cell death, which 
results in nuclear and cytoplasmic condensation, resulting in the formation of 
apoptotic bodies (107, 109). These apoptotic bodies are then engulfed by 
neighbouring cells and degraded in a controlled manner, thus avoiding immune 
activation (107, 109). Fas-mediated apoptosis can be further characterised into two 
pathways; the extrinsic (death receptor) pathway, and the intrinsic (mitochondrial) 
pathway (110), with FADD, the adapter protein of the Fas signalling pathway, also 
contributing to programmed necrosis (necroptosis) (111).  
The extrinsic pathway is induced upon binding of FasL to the Fas receptor, present 
on the plasma membrane, resulting in activation of the Fas signalling pathway (112). 
Upon activation, the intracellular domain of the receptor undergoes a conformational 
change (113), resulting in recruitment of the adapter protein FADD to Fas, through 
DD-DD interactions (114). FADD then recruits procaspase-8 (115, 116), procaspase-
10 and cellular FADD-like IL-1β-converting enzyme-(FLICE)-inhibitory protein 
(cFLIP), a regulator of caspase-8/10 activation (117) through DED-DED 
interactions. This results in the formation of the Death Inducing Signalling Complex 
(DISC) around the cytoplasmic tail of Fas (115), with internalization of the receptor 
required for efficient DISC formation (118). Oligomerization of procaspase-8 
occurs, resulting in auto-proteolytic cleavage of procaspase-8, which results in the 
activation of caspase-8. In type I cells, sufficient amounts of caspase-8 are activated 
at the DISC to trigger activation of additional caspases (119), including the effector 
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caspases, caspase-3 and caspase-7 (120). This results in enhancement in caspase 
activity and apoptotic death of the cell (118).  
However, if insufficient levels of caspase-8 activation occur due to reduced DISC 
formation, the Fas signalling pathway has a compensatory mechanism, which utilises 
the mitochondria for activation of the effector caspases, resulting in activation of 
Fas-induced intrinsic apoptotic pathway (120). These are known as type II cells 
(121). In these cells, caspase-8 activation results in the cleavage of the protein Bid, a 
member of the Bcl-2 family of proteins present in the cytoplasm (122). This results 
in the formation of truncated Bid (tBid) which translocates to the mitochondria, 
causing the aggregation of both Bax and Bak, two members of the Bcl-2 family of 
proteins (123). This then results in the release of second mitochondria-derived 
activator of caspase (SMAC) and cytochrome c from the mitochondria, with the 
latter forming a complex with apoptotic protease-activating factor-1 (Apaf-1), 2’-
deoxyadenosine 5’triphosphate (dATP) and procaspase-9, resulting in the activation 
of the initiator caspase in this apoptosome complex (121, 124). Caspase-9 can in turn  
activate the effector caspase, caspase-3, resulting in apoptosis of the cell (figure 
1.6a) (123).  
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Figure 1.6a: The Fas/FasL-induced apoptotic signalling pathways 
Recognition of FasL by its receptor Fas results in the oligomerisation of the receptor, 
initiating DISC formation. Auto-proteolytic cleavage of procaspase-8 occurs 
resulting in the activation of downstream effector caspases, and ultimately cell death. 
Reduced levels of caspase-8 can also activate the mitochondrial cell-death pathway, 
mediated by the activation of Bid, resulting in the release of cytochrome c from the 
mitochondria, resulting in the activation of Apaf-1 and caspase-9, culminating in 
apoptosis. 
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It is thought that inhibitors of apoptosis (IAPs), composed of cIAP1/2 and X 
chromosome-linked inhibitor of apoptosis protein (XIAP) may also regulate Fas-
mediated apoptosis. XIAP, cIAP1 and cIAP2 are thought to all bind and inhibit 
caspase-3, -7 and -9, whilst having no effect on caspases-1, -6, -8 or -10 (125, 126). 
In the absence of caspase activation, Fas activation can result in necroptosis (127, 
128). The requirement for the Fas adapter protein FADD in necroptotic signalling 
has also been demonstrated (129, 130). Necroptotic signalling is mediated through 
formation of a signalling complex composed of RIP1, RIP3, FADD and caspase-8, 
termed the Ripoptosome, with its formation occurring independent to other death 
receptor signalling pathways (127, 129, 130). Ripoptosome formation is regulated by 
the IAPs, as well as cFLIP (129). IAPs mediate ubiquitination of RIP1, thereby 
limiting its availability for Ripoptosome formation (130). cFLIP is a negative 
regulator of Ripoptosome formation, with increased levels of cFLIP reducing 
Ripoptosome formation (129) by limiting the availability of FADD for complex 
formation. Studies have demonstrated that the kinase activity of both RIP1 and RIP3 
are essential components for Ripoptosome formation, with formation of this complex 
inducing either apoptotic (caspase dependent) or necroptotic (caspase independent) 
signalling (figure 1.6b) (108, 129).  
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Figure 1.6b: Fas activation and necroptosis 
 
Fas activation in the absence of caspase activity results in necroptosis of the cell. 
Necroptotic signalling is mediated by a complex containing RIP1, RIP3, FADD and 
caspase-8, with the kinase activity of RIP1 and RIP3 capable of inducing 
necroptosis. 
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1.3.5 Apoptotic functions of Fas 
The Fas signalling pathway is an important means of maintaining immune privileged 
sites such as the eye, testis, ovary and placenta. Local expression of FasL targets 
invading Fas expressing cells, resulting in apoptosis. This limits inflammation, thus 
limiting any collateral damage from inflammatory events, maintaining anatomical 
integrity of these sensitive sites (97, 98, 131). Immune privilege may also be utilised 
by tumours to evade the immune system, with tumour cells expressing FasL 
inducing Fas-mediated apoptosis of infiltrating immune cells, thus allowing 
progression of the tumour (121, 132, 133).  
The Fas signalling pathway plays a vital role in T cell homeostasis. This becomes 
apparent when the Fas signalling pathway is interrupted, resulting in dysregulation 
of Fas-induced apoptosis. It has been demonstrated in mice which contain mutations 
in Fas (lpr) or FasL (gld) that interruption of the Fas signalling pathway disrupts 
Fas-mediated apoptosis and as a result, disrupts T cell homeostasis resulting in 
lymphoproliferative disorders, as well as autoimmune conditions such as arthritis 
and systemic lupus erythromatosis (SLE) (134, 135). This is similar to the human 
condition, autoimmune lymphoproliferative syndrome (ALPS) which is caused by 
mutation in components of the Fas signalling pathway, preventing Fas signalling. 
This results in lymphoproliferation and a predisposition of these individuals to 
develop lymphomas (136-138). 
1.3.6 Non-apoptotic Functions of the Fas signalling pathway 
Whilst Fas is classically associated with apoptosis, recent studies have demonstrated 
that the Fas signalling pathway is multifaceted and is involved not only in T cell 
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homeostasis and the maintenance of immune privileged sites, but can also trigger 
migration, proliferation and inflammation (figure 1.7).  
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Figure 1.7: The functions of the Fas signalling pathway 
In addition to apoptosis, the Fas/FasL pathway has been shown to induce migration, 
invasion, proliferation and inflammation. 
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Proliferation 
Whilst studies have demonstrated that naïve T cells are resistant to Fas-mediated 
apoptosis, ligation of Fas induces proliferation of these cells (139, 140). Proliferation 
of T cells also occurred with regard to memory T cells due to their prior exposure to 
an antigen (141). T cells require two main signals for activation. Signal 1 results 
from engagement of the T cell receptor (TCR)/CD3 complex, with signal 2 provided 
by either IL-12, IL-4, or ligation with CD28. Activation of the TCR/CD3 complex in 
the absence of signal 2 would result in Fas-mediated apoptosis of naïve T cells. 
However, TCR/CD3-stimulated memory T cells in the absence of signal 2 do not 
undergo Fas-mediated apoptosis following Fas ligation. It has been demonstrated 
that co-stimulation of memory T cells with TCR/CD3 with Fas activation results in 
proliferation of memory T cells (141). Studies have also demonstrated that Fas 
activation can also induce proliferation of tumour cells, whereby a reduction in Fas 
or FasL expression resulted in reduced proliferation, possibly as a result of reduced 
JNK and ERK MAPK activation (142, 143). Fas and FasL are widely expressed in 
the nervous system (144, 145) with studies demonstrating that following sciatic 
nerve injury in vivo, Fas activation enhanced nerve regeneration (88).  
 Migration/Invasion 
Fas ligation can also result in migration and invasion in apoptosis resistant cells, 
with stimulation of tyrosine kinase activity by Fas implicated in these processes 
(146). Fas induces tyrosine kinase activity, resulting in phosphorylation of caspase-8 
(147), the scaffold protein TRIP6 (148), and the catalytic subunit of 
phosphatidylinositol-3-kinase (p110-PI3K) (149) however the sequence in which 
this occurs is unclear (146). Caspase-8 then becomes a docking site for Src 
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homology domain 2 (SH2) containing proteins, recruiting them to the Fas complex 
(146). Recruitment of Yes and p85-PI3K, members of the Src-family kinase, to the 
Fas complex results in PI3K activation. This results in the activation of Akt which, 
following a series of signalling events, can activate either NFκB through interaction 
with the caspase8/RIP1/TRAF2 signalling complex, or the Wnt pathway, inducing 
the expression of metalloproteases (MMPs) and urokinase plasminogen activator 
(uPA) (110, 146).  Studies have demonstrated that expression of MMP9 results in 
increased migration of cells, with MMPs aiding the migration of cells through the 
extracellular matrix (110, 146). 
Inflammation 
Fas activation has also been implicated in inflammation (figure 1.8). Fas activation 
by the agonistic Fas antibody CH11 induced the production of TNFα, IL-8 and IL-10 
in human monocyte-derived macrophages (150). This study demonstrated that 
human monocyte-derived macrophages were resistant to apoptosis, and therefore the 
inflammatory effect was not a by-product of cell death (150). They also 
demonstrated that Fas-induced cytokine production was independent of caspase 
activation (150).  
It has also been observed that priming of macrophages with LPS induced Fas 
expression in macrophages which, upon ligation of Fas, resulted in the production of 
IL-1β and IL-18 (151). Whilst associated with the inflammasome, the maturation and 
secretion of IL-1β and IL-18 were determined to be independent of the 
inflammasome components NLRP3, ASC and caspase-1. Thus they concluded that 
Fas ligation induced the expression of these cytokines in a non-canonical manner 
(151).  
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Fas ligation can induce the phosphorylation of MAPKs (152, 153). The MAPKs are 
thought to play a key role in cytokine production, particularly ERK1/2 and JNK 
MAPKs. Studies have demonstrated that inhibition of the MAPKs resulted in 
inhibition of IL-8 production (152, 154). MAPK activation resulted in the activation 
of the transcription factors AP-1 and NFκB, inducing cytokine production (155).  
Whilst it is well established that the MyD88 adapter protein facilitates TLR-induced 
cytokine production, it has now been demonstrated that MyD88 may be implicated 
for Fas-induced inflammation (156). In this study, they demonstrated that while Fas 
induced the production of inflammatory cytokines, in the absence of MyD88 
cytokine production in both RAW264.7 macrophages, as well as peritoneal 
macrophages derived from MyD88
-/-
 mice was diminished, with cytokine production 
occurring independent of caspase activation (156). Consistent with this, MyD88 was 
shown to be required for Fas-induced production of CXCL-1/KC by alveolar 
epithelial cells. This was also demonstrated to occur independent of caspase 
activation (154). 
Together, these studies have demonstrated that Fas activation can indeed result in the 
production of inflammatory cytokines. As the Fas adapter protein FADD has been 
implicated in a number of innate immune receptor signalling pathways, it has now 
been demonstrated that Fas activation modulates their cytokine production .This 
occurs following recruitment of FADD to the DISC complex. This reduces the level 
of FADD present in the cytosol, thereby removing its effect from these immune 
receptors (157-159). 
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Figure 1.8: Fas-induced inflammation is induced by different signalling 
pathways. 
Fas-mediated inflammation may be induced via activation of the NFκB transcription 
factor, or activation of ERK, p38 and JNK MAPK signalling pathways downstream 
of the DISC. MyD88 may directly interact with Fas in a FADD independent manner, 
resulting in Fas-mediated inflammation. Signalling pathways/intermediaries which 
are not fully elucidated are represented by dashed lines.  
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1.4 Cross-talk between Fas and Toll like receptors 
Studies have demonstrated that the Fas signalling pathway can modulate TLR-
induced cytokine production (158, 160-162). Interruption of the Fas signalling 
pathway reduced the expression of LPS-induced IL-6 production in macrophages 
(158), whilst Fas activation enhanced both LPS- and Flagellin-induced cytokine 
production in intestinal epithelial cells (160). Recruitment of inflammatory cells and 
therefore cytokine production was also reduced in cardiac dysfunction by blocking 
Fas signalling (161, 162).  
The Fas adapter protein FADD has also been reported to play a negative regulatory 
role in TLR4 signalling (157-159). Studies have demonstrated that LPS-induced 
NFκB activation was reduced following overexpression of FADD (157, 158). It has 
also been demonstrated that LPS-induced NFκB activation was enhanced in FADD-/- 
MEFs (157), with FADD regulating NFκB activation through interaction with 
MyD88, one of the four adapter proteins utilised by TLR4 (158, 159) and IRAK1 
(159) through DD-DD interactions, with IRAK1 proving essential for formation of 
this complex (159). These studies demonstrated a regulatory role for FADD in LPS-
induced cytokine production using overexpression studies or removal of FADD from 
the cell.  
Studies have demonstrated that viruses can modulate the Fas signalling pathway to 
their advantage (163, 164). Both equine herpesvirus type 2 (EHV-2) protein E8 and 
molluscum contagiosum virus (MCV) MC159 protein are DED containing proteins. 
It has been demonstrated that E8 interacts with the DED of caspase-8 prodomain, 
whilst MC159 binds to the DED of FADD, thereby preventing the activation of Fas-
mediated apoptosis, resulting in the persistent infection of cells by these viruses 
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(163). Studies have also demonstrated that infection of cells with HSV-2 enhanced 
the expression of Bcl-2, thus protecting against Fas-induced apoptosis and resulting 
in the establishment of a persistent infection (164).   
The role of FADD however is more defined in terms of viral infection. Studies have 
shown that FADD is required for RIG-I and MDA5 induced type 1 IFN production 
(165, 166). They demonstrated that RIG-I-induced IFNβ production was 
significantly reduced in FADD
-/-
 MEFs following poly I:C stimulation as compared 
to wild-type cells, with reconstitution of FADD
-/-
 MEFs  with FADD restoring their 
ability to produce IFNβ (165). This group also demonstrated that FADD is 
associated with activation of secondary IFNα genes, with a reduction of IRF7 
activation observed in FADD
-/-
 MEFs following viral stimulation mediating its effect 
through IRF7 activation (166). 
Therefore, while it is apparent that FADD is implicated in the innate immune 
system, its role is somewhat unclear. 
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1.5 Aim of this study 
The Fas signalling pathway is well characterised in terms of its ability to induce 
apoptosis. Studies now demonstrate that this pathway also mediates inflammatory 
cytokine production, with an increasing body of data indicating that there is crosstalk 
between the TLR and Fas signalling pathways both in terms of crosstalk between the 
receptors themselves and crosstalk between the adaptor proteins in both pathways. 
Work in this field has been restricted to studies examining crosstalk between Fas and 
TLR4 with no studies investigating crosstalk between Fas and other TLRs. In 
addition there are very few studies investigating both Fas and FADD together in 
terms of their ability to modulate TLR responses.  In this study we sought to 
examine the crosstalk between Fas and TLRs and the effect of Fas activation on TLR 
signalling, in particular, TLR3, and TLR4. Studies have alluded to the fact that 
crosstalk may be implicated in the modulation of TLR3- and TLR4-mediated 
antiviral signalling, as RIGI and TLR3, apart from their adapter proteins, share 
similar downstream signalling components. Equally, these signalling components are 
shared by the MyD88-independent signalling pathway of TLR4. To our knowledge, 
no study has implicated Fas activation on this pathway. Therefore, we sought to 
investigate more thoroughly the impact of Fas activation on TLR signalling 
pathways.  
 Specific Aims: 
1. To investigate the role of Fas in the induction of anti-viral cytokine and 
chemokine responses, and to investigate whether there was a potential role 
for Fas in modulating poly I:C-induced cytokine and chemokine responses 
(Chapters 3, 4). 
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2. To further characterise the role of both Fas and its adapter protein FADD in 
modulating TLR4-induced inflammation using the agonistic Fas antibody, 
CH11, and also to identify any potential novel FADD interacting proteins 
(Chapter 5).   
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Chapter 2 
Materials and Methods 
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2.1 Cell Culture 
The leukemic monocytic cell line THP1 and Jurkat T cell line was obtained from the 
European Collection of Cell Cultures (ECACC). Human embryonic kidney cells 
stably transfected with either TLR3 or TLR4 (HEK293/TLR3, HEK293/TLR4) were 
obtained from Invivogen (San Diego, CA). HEK293T cell line and the murine 
macrophage cell line RAW264.7 were kindly donated by Dr. Ken Nally 
(Ailimentary Pharmabiotic Centre, UCC). The astrocytoma cell line U373 was 
kindly donated by Dr. Luke O’Neill (Trinity College Dublin). Both wild-type and 
FADD deficient murine embryonic fibroblasts (MEFs) were kindly donated by Dr. 
Tak Mak (University Health Networ, Ontario, Canada). Wild-type and TRIF 
deficient immortalised bone marrow-derived macrophages (iBMDMs) were kindly 
donated by Dr. Sinead Miggin (Maynooth University, Co. Kildare, Ireland). 
THP1 monocytic cell line and Jurkat T cell line were maintained in Roswell Park 
Memorial Institute (RPMI)-1640 media (Sigma-Aldrich, Dorset, UK) supplemented 
with 10% (v/v) foetal calf serum (FCS) (Sigma-Aldrich) and 1% (w/v) 
penicillin/streptomycin (pen/strep) (Sigma-Aldrich). HEK-293T, RAW264.7, U373, 
MEFs and iBMDMs were all maintained in Dulbecco’s Modified Eagles Medium 
(DMEM) supplemented with 10% (v/v) FCS and 1% (w/v) pen/strep. 
HEK293/TLR3 and HEK293/TLR4 cell lines were maintained in DMEM 
supplemented with 10% FCS and 1% pen/strep, with selective antibiotics, with 
HEK293/TLR3 cells requiring 10mg/ml Blasticidin (Invivogen, San Diego, CA), 
with 10mg/ml Blasticidin (Invivogen) and 100mg/ml HygroGold (Invivogen) 
required for HEK/TLR4 cells.  
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Mycoplasma testing was performed quarterly using Mycoplasma Detection Kit 
(Invivogen). Cells were incubated without antibiotics for 48 hours. Cell culture 
supernatant was collected. A 500μl sample of cell culture supernatant was then heat 
inactivated and incubated with genetically engineered HEK-Blue cells for 24 hours. 
The presence of Mycoplasma was detected as follows: no colour change (pink 
colour) indicates a negative result and a blue/purple colour indicates the presence of 
Mycoplasma. All cell cultures used in these experiments tested negative. 
2.2 Differentiation of THP1 monocytic cells into THP1 monocyte-derived 
macrophages 
THP1 monocytes were seeded in 6 well plates at a concentration of 1 x 10
6
 cells per 
well in full RPMI-1640 media, supplemented with 100ng of phorbal 12-myristate 
13-acetate (PMA) (Sigma-Aldrich) (167). THP1 monocytic cells were allowed to 
differentiate for 72 hours. Media was then changed, and macrophages were allowed 
to rest overnight, following which stimulations occurred.   
2.3 Human monocyte derived macrophages 
Human monocytes were obtained from healthy volunteers. A minimum of 28ml of 
fresh whole blood was collected into ethylene diamine tetra-acetic acid (EDTA) 
vacutainers. One sample was centrifuged at 1200 x g for 20mins to retrieve the 
plasma which is used to supplement the media. Fresh samples were added into 50ml 
conical flasks, with 3mls Ficoll-Hypaque (Sigma-Aldrich) added for every 7mls of 
blood. Samples were centrifuged at 670 x g for 30mins with no brake applied. The 
buffy coat was then removed using sterile pipettes. Cells were washed by adding 
three times the volume of Hanks buffered salt solution, and centrifuged at 283 x gg 
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for 10minutes. Supernatant was removed, and cells washed twice more as described. 
Mononuclear cells were suspended in RPMI-1640 supplemented with 1% (w/v) 
pen/strep and 2% (v/v) of subject’s serum and seeded in 24 well plates as required. 
Cells were seeded and allowed to adhere for 4 days. Non-adherent cells were 
removed with remaining cells gently washed three times with RPMI-1640 
supplemented with 1% (w/v) pen/strep and 2% (v/v) of subject’s serum. Media was 
replaced and cells were allowed to fully differentiate for a further 3 days.  
2.4 Caspase 3/7 Assay 
Cells were seeded overnight in black flat-bottomed 96-well plates at a density of 
20,000 cells/well. Cells were pre-treated with human agonistic Fas antibody (clone 
CH11) (Merck-Millipore, Darmstedt, Germany) for 1 hr and subsequently with 20 
µg/ml polyinosinic:polycytidylic acid (poly I:C) or 100ng/ml lipopolysaccharide 
(LPS) for 24 hr. Alternatively, cells were treated with each agonist separately.  Apo-
ONE caspase-3/7 reagent (Promega, Madison, USA) was added and following 1 hr 
incubation, fluorescence (485 excitation, 530 emission) was measured using a 
GENios Microplate Reader (Tecan Group Ltd, Männedorf, Switzerland). Changes in 
caspase 3/7 activation were normalised relative to untreated cells. 
2.5 Viability Assay 
Cells were untreated or were stimulated with poly I:C (Sigma-Aldrich), poly A:U 
(Sigma-Aldrich), and/or CH11 (Merck-Millipore) as indicated in the figure legends. 
Cells were trypsinised with trypsin neutralised using double the volume of medium. 
Cells were centrifuged at 170 x g for 3 mins and pellets resuspended in 1ml of 
media. A 1:10 dilution was then performed with 10μl of cell suspension added to 
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90μl trypan blue (Sigma Aldrich). 10μl of this cell suspension was added to a 
haemocytometer. Trypan blue is excluded from living cells due to the presence of 
intact cell membranes (168). Cell counts were performed on both living and dead 
cells across all treatment groups. 
2.6 Murine bone marrow-derived macrophages 
Mice were sacrificed and femur and tibia bones were removed and cleaned with 1X 
sterile PBS and 70% ethanol. Bones were placed in sterile 1X PBS. To isolate bone 
marrow both ends of the bone were cut and, using a 5ml syringe, bone marrow was 
flushed through with sterile cold PBS. Isolated bone marrow was re-suspended to 
generate a single cell suspension and passed through a 45μm cell filter strainer. The 
cell suspension was centrifuged at 4°C at 380 x g for 5 minutes. The cell pellet was 
washed once in BMDM culture media (DMEM, 10% (v/v) foetal bovine serum, 1% 
(v/v) pen/strep, 1% L-Glutamine, 1% non-essential amino acids) and centrifuged at 
4°C at 380 x g for 5 minutes. The cell pellet was re-suspended in BMDM 
differentiating media (BMDM culture media supplemented with 30% (v/v) L929 
conditioned media) for 7 days to allow for macrophage progenitors to differentiate 
into mature macrophages. The cells were cultured on 100mm sterile Petri dishes. On 
day 3 of differentiation, fresh differentiating culturing media was added. Any non-
adherent cells were removed at this stage. Adherent cell differentiate into BMDM 
over the 7 day period. After 7 days the cells were cultured in BMDM media without 
L929 conditioned media. 
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2.7 Stimulation of Cells 
THP-1 macrophages were pre-treated with 100ng/ml CH11 (Merck-Milipore), for 1 
hour prior to stimulation with either 100ng/ml LPS or 20μg/ml poly I:C (Sigma-
Aldrich) for either 8 hours for RNA expression or 48 hours for protein expression 
unless stated otherwise. 
2.8 Poly I:C-induced Fas and FasL expression of THP1 macrophages 
THP1 monocytes were seeded to a final concentration of 1 x 10
6
 cells/ml and 
allowed to differentiate into macrophages as described. Cells were then treated with 
poly I:C at concentrations of 5μg/ml, 10 μg/ml, 20 μg/ml and 40 μg/ml and 
incubated for either 8 hours for mRNA expression, or 24 hours for protein 
expression. An untreated control was also included. 
2.9 LPS-induced Fas, FasL and FADD expression in THP1 macrophages 
THP1 monocytes were seeded to a final concentration of 1 x 10
6
 cells/ml and 
allowed to differentiate into macrophages as described. Cells were then treated with 
LPS at concentrations of 25ng/ml, 50ng/ml, 100ng/ml, 200ng/ml and 400ng/ml and 
incubated for either 8 hours for RNA expression, or 24-72 hours for protein 
expression. An untreated control was also included. 
2.10 CH11-induced TLR3 and TLR4 expression in THP1 macrophages 
THP1 monocytes were seeded to a final concentration of 1 x 10
6
 cells/ml and 
allowed to differentiate into macrophages as described (Section 2.1.2). Cells were 
then treated with 25ng/ml, 50ng/ml, 100ng/ml and 200ng/ml of CH11 (Merck- 
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Millipore) for either 8 hours for RNA expression or 24 hours for protein expression. 
An untreated control was also included.  
2.11 Sample Preparation - Western Blotting  
Cells were rinsed once in ice cold 1x PBS and either lysed directly in 200μl Laemmli 
buffer supplemented with 1mM DTT (Sigma-Aldrich) and stored at -20
o
C, or lysed 
on ice for 1 hour with 100μl of lysis buffer (50mM tris-hydroxymethyl) amino 
methane (Tris-Cl, 150mM sodium chloride (NaCl), 1% (w/v) Triton x-100) 
supplemented with 1x protease an phosphatase inhibitor cocktail (both from Merck-
Millipore). Cells were then scraped and transferred to a 1.5ml eppendorf.  Samples 
lysed in lysis buffer were centrifuged at 14000 x g at 4
o
C for 10 minutes. The 
resulting cell debris was discarded and lysate stored at -20
o
C.  
2.12 Bicinchoninic Acid (BCA) Assay 
Protein standards were prepared using Bovine Serum Albumin (BSA) (Thermo 
Scientific, IL, USA) (0, 2.5, 5, 7.5, 10, 15, 20μg/ml) and added to a 96 well plate.  
2μl of each sample was added to the plate followed by 38μl of dH20.  Both standards 
and samples were analysed in triplicate. 160μl of BCA Protein Assay Reagent 
(Thermo -Scientific) was added to each well, the plate agitated and then left at 37°C 
for 30 minutes before reading at 595nm on a spectrophotometer. A standard curve 
was then generated  using GraphPad Prism software and used to calculate the protein 
concentrations of unknown samples.  
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2.13 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and Western blotting 
50µg of cell supernatant protein was mixed with 5 x PAGE loading buffer (125mM 
Tris, 2% SDS, 20% Glycerol, 2.5% beta mercaptoethanol) and lysis buffer 
(described above) to a final volume of 20μl. Samples were boiled for 5 minutes, with 
20μl loaded onto a separating and stacking SDS gel.  A 19-180 kilodalton (kDa) 
molecular weight marker (Sigma-Aldrich) was run alongside the samples.  Proteins 
were separated by electrophoresis at 40mA/A and then transferred for 90 minutes at 
room temperature onto an Immobilon –P polyvinylidene diflouride membrane (I-
PVDF) (Millipore, CA, USA) at 120V/V using a wet transfer method. Protein 
loading and efficiency of transfer were monitored by Ponceau S staining for all 
experiments except those using phospho-antibodies. With the exception of phospho-
antibodies which were blocked in 5% (w/v) BSA in 0.1%TBS/Tween-20, 
membranes were blocked for 1 hour at room temperature in BLOTTO (5% (w/v) 
non-fat dry milk in 0.1% PBS/Tween-20) and then incubated overnight at 4
o
C with 
the appropriate primary antibody (Table 2.1). With the exception of phospho-
antibody membranes which were washed in 0.1% TBS/Tween-20, membranes were 
washed with PBS/0.1% Tween-20 for 5 x 5 minutes, with primary antibodies 
detected by incubating the membrane for 1 hour at room temperature with the 
appropriate horseradish peroxide (HRP)-conjugated IgG secondary antibody (Dako 
Corp., Carpinteria, CA). Peroxidase activity was detected with the enhanced 
chemiluminescence system (ECL) (Millipore, Billerica, MA) using the FujiFilm 
LAS-3000 Lightbox. As a loading control, duplicated membranes were blocked for 1 
hour in BLOTTO and incubated overnight at 4
o
C with anti-β actin specific antibody 
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(Table 2.1). The primary antibody was detected using anti-mouse HRP secondary 
antibody (Dako Corp.). 
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Table 2.1 Antibodies used for Western blotting and immunofluorescence. 
Antibody Cat. Number Company 
TLR4 (H-80) sc-10741 Santa Cruz 
Fas (C-20) sc-715 Santa Cruz 
FADD H-10 sc-271520 Santa Cruz 
FasL 555290 Abcam 
Monoclonal Anti-VSV Glycoprotein 
P5D4 
V5507 Sigma-Aldrich 
Anti-Flag F1804 Sigma-Aldrich 
βactin AAC-74 Sigma-Aldrich 
Phospho-Antibodies Cat. Number Company 
phospho-IκBα 133462 Abcam 
phospho-p42/44 MAPK 9101s Cell Signaling 
phospho-p38 MAPK 9211s Cell Signaling 
phospho-JNK 9251s Cell Signaling 
Secondary HRP antibodies Cat. Number Company 
Polyclonal Rabbit anti-Mouse P0260 DAKO 
Polyclonal Mouse anti-Rabbit P0448 DAKO 
Fluorescent labelled Secondary 
antibodies 
Cat. Number Company 
Donkey anti-rabbit Texas Red (TR) sc2784 Santa Cruz 
Donkey anti-mouse Fluorescein 
isothiocyanate (FITC) 
sc2099 Santa Cruz 
52 
 
2.14 Immunofluorescence  
Cells were seeded at 1x10
5
 cell/ml onto EZ slides (Millipore). Cells were then fixed 
in 100% ice-cold methanol for 5 mins the following day.  Cells were permeabilsed 
using 0.2% (w/v) Trition X-100 in PBS for 30mins before blocking in 10% (v/v) 
normal donkey serum (Sigma-Aldrich) for 1hr at room temperature.  The slide was 
incubated with primary antibody overnight in 1.5% (v/v) normal donkey serum at 
4°C.  The following day, the slide was washed three times in PBS and incubated in 
the appropriate secondary antibody diluted in normal donkey serum for 1 hour before 
counterstaining with 4’ 6-Diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). DAPI 
preferentially stains dsDNA, binding to AT-rich regions of DNA, emitting a blue 
fluorescent hue (169). Anti-fade fluorescent mounting media (Dako) was utilised 
when applying coverslips to impede fading of fluorescence, with slides stored in the 
dark following application of cover-slips. Emission of primary or only secondary 
antibody negative controls were also included.   
2.15 Quantitative Real Time PCR (qRT-PCR) 
Total RNA was isolated using either the GenElute Mammalian Total RNA Mini 
Prep kit (RT-70-1KT, Sigma-Aldrich) or the ISOLATE kit (Bioline, UK) according 
to the manufacturer’s instructions. 10 µl of total RNA was used as the template for 
cDNA synthesis (Bioline, UK).  This was added to 1μl of Oligo (Dt), and 1μl of 
10mM dNTP and heated to 65°C for 10 minutes.  Following 2 minutes on ice, 4μl of 
5x Reverse Transcriptase Buffer, 1μl of RNase inhibitor, 0.25μl of Reverse 
Transcriptase, and 2.75μl of DEPC treated water was added to each sample before 
incubation at 37
o
C for 30 minutes. The reaction was terminated by a final incubation 
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at 70°C for 15 minutes and chilling samples on ice. cDNA samples were then diluted 
to 100μl using DEPC water (Sigma-Aldrich).  
TaqMan MasterMix was used with TaqMan Gene Expression probes Fas, FasL, 
TLR3, TLR4, RIG-I, IL-8, IL-10, IL-12, TNFα, IFNβ, hIP-10/CXCL-10 and mIP-
10/CXCL-10, mIFNβ (table 2.2) (Bio-Sciences, Dublin, Ireland) with qRT-PCR 
analysis performed using LightCycler instrument (Applied Biosystems). PCR 
reactions for CCL-20 were performed using 900nM of CCL-20 and 250nM of Sensi 
Mix II (BioLine, London, UK) in the LightCycler 480 Real-Time PCR System 
(Roche) software. Thermal cycling conditions were as recommended by the 
manufacturer (Roche). Table 2.3 below contains the primer sequences used for CCL-
20.  ΔΔCt analysis (170) was performed using Microsoft Excel. 
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Table 2.2 qRT-PCR reaction conditions for TaqMan method. 
 Left Primer Right Primer UPL# 
CCL-20 5’ gctgctttgatgtcagtgct 3’ 5’ gaagaatacggtctgtgtatccaa 3’ 39 
β-actin 5’ attggcaatgagcggttc 3’ 5’ tgaaggtagtttcgtggatgc 3’ 11 
Table 2.3: Sequences of primers used in qRT-PCR analysis. Primers were 
generated by Eurofins MWG (www.eurofinsgenomics.eu). 
Gene Name Probe Reaction Conditions 
Human  
 
 
 
50
o
C for 2 mins  
95
o
C for 10mins 
60 cycles@ 95
o
C for 
15secs and 60
o
C for 15sec 
Fas Hs00236330_m1 
FasL Hs00181225_m1 
IL-8 Hs99999034_ml 
TNFα Hs00174128_m1 
IFNβ Hs00277188_s1 
IL-10 Hs00961622 
IP-10 Hs00171042_m1 
IL-12 Hs01073447_m1 
TLR3 Hs01551078_m1 
TLR4 Hs00370853_m1 
RIG-I Hs00204833_m1 
GAPDH GAPDH, 4352934E 
Murine 
IP-10 Mm00445235_m1 
IFN β Mm00439552 
β-actin β-actin, 4352341E 
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2.16 Migration and Attachment of T cells to THP1 monocyte-derived 
macrophages 
Sterile coverslips were placed in each well of a 6 well plate. THP1 monocytes were 
seeded and allowed to differentiate as described. Stimulations were performed for 24 
hours, following which Jurkat T cells were co-cultured for a further 48 hours. 
Coverslips were then washed in PBS and mounted on slides. Bright field microscopy 
was then performed. 
2.17 Transwell Migration Assay 
Jurkat T cells were cultured overnight in THP1 macrophage-derived supernatant to 
induce CXCR-3 expression. 750μl of THP-1 macrophage treated cell culture 
supernatant was added to each well of a 24 well plate, with 200μl of Jurkat T cells at 
a concentration of 1.25 x 10
6
 cells/ml in serum free media added to the chamber. 
Plate was incubated at 37°C for 2 hrs, following which the upper chamber was 
removed, with the contents of the well collected. Samples were centrifuged at 12,400 
x g for 5 mins, with sample incubated on ice between each centrifuge cycle. Cells 
were washed twice in PBS and fixed in ice cold methanol for 5 minutes. Cells were 
then stained in 0.1% (w/v) crystal violet in 0.1M borate pH 9.0 and 2% (v/v) ethanol 
for 20mins. Cells were then washed 3 x 5mins in PBS, with supernatant removed 
after each step. Elution of stain was then performed using 200μl of acetic acid and 
vortexing periodically over 15mins. Cells were centrifuged at 12,400 x g for 3 min, 
with supernatant collected and absorbance read at 570nm. 
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2.18 Flow Cytometry 
THP1 macrophages were treated with 20μg poly I:C, 100ng CH-11, and pre-
stimulated with 100ng CH-11 prior to poly I:C stimulation. Stimulations progressed 
for 48 hours. Supernatant from each treatment was then collected and centrifuged for 
3 mins at 170 x g to remove any residual cells. This supernatant was then added to 
individual wells of a 6 well plate, with Jurkat T cells then seeded in this supernatant 
and incubated for 24 hours at 37°C with 5% CO2. CXCR-3 FITC conjugated 
antibody (MSC) was applied to cells as per manufacturer’s protocol, with 
appropriate isotype control (Santa Cruz BioTechnology, Dallas, TX). Flow 
cytometry was performed on the Facscaliber flow cytometer with analysis performed 
using Cell Quest Pro software.  
2.19 Transformation of competent DH5α cells by heat-shock 
DH5α cells were thawed on ice with 2μl of plasmid added to 25μl of competent cells 
(Bio-Sciences, Dublin). Suspension was left on ice for 30mins. Cells were then 
heated to 42°C for 2 mins, and immediately cooled on ice for 2 mins. 1ml LB broth 
was added, with suspension incubated at 37°C for 1hr with agitation. 100μl of this 
cell suspension was then plated onto agar plates containing selective antibiotic, e.g. 
1mg/ml ampicillin. Plates were left overnight at 37°C, with colonies detected the 
following day. A single colony was then picked and added to 1ml of LB broth with 
selective antibiotic (starter culture). The starter culture was incubated at 37°C for 
8hrs. 100μl of this starter culture was then added to 100ml of LB broth with selective 
antibiotic in sterile conical flasks and incubated with agitation overnight at 37°C 
with the bacterial culture then ready for plasmid extraction. 
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2.20 MaxiPrep 
Plasmids were purified following the protocol for using the EndoFree Plasmid 
Purification Kit (Qiagen). Bacterial cultures generated above were harvested by 
centrifugation at 6000 x g for 60mins in a refrigerated centrifuge. The pellets were 
then lysed according to the manufacturer’s instructions. Precipitate was removed 
using the QIAfilter Cartridge which removes the proteins, genomic DNA and 
detergent contained within the precipitate. Endotoxin was removed by addition of an 
endotoxin removal buffer (Buffer ER), with suspension added the QIAGEN-tip. The 
QIAGEN-tip is an anion-exchange tip which utilises positively charged 
diethylaminoethyl (DEAE) bound to the resin. The positive charge of DEAE then 
binds to the negatively charged phosphates of the DNA backbone forming a complex 
whilst removing other impurities. The QIAGEN-tip was then washed twice, with 
DNA eluted using elution buffer provided. Isopropanol was added to the DNA and 
centrifuged at 6000 x g for 60mins at 4°C. The supernatant was removed, with 5ml 
of endotoxin free room-temperature 70% ethanol added, with sample centrifuged at 
6000 x g for 60mins at 4°C. Supernatant was carefully removed with pellet allowed 
to air-dry for 10mins. Pellet was then resuspended in 200μl endotoxin-free Buffer 
TE. The yield was then determined by measuring the plasmid DNA using the 
NanoDrop Spectrophotometer. 
2.21 Luciferase/Plasmids 
All cells were seeded in 200μl at 2 x 105 cells/ml in 96 well plates, with the 
exception of RAW264.7 which were seeded in 1ml at 1.5 x 10
5
 cells/ml in 24 well 
plates. RAW264.7 cells were transfected using Turbofect (Fermentas, Thermo Fisher 
Scientific, Waltham, MA, United States of America) with HEK cells and U373s 
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transfected with GeneJuice (Merck Millipore) according to the manufacturer’s 
protocol. Cells were transfected with 40ng of full length IP-10 promoter, IP-10 
containing point mutations in the ISRE, κB1, κB2 and the AP-1 binding sites (kind 
gifts from Prof. David Proud), full length mIP-10 promoter (a kind gift from Dr. 
Daniel Muruve, UC Calgary, Canada), IFNβ, ISRE, NFκB luciferase plasmid, and 
5ng of Thymidine kinase Renilla luciferase (TK Renilla), along with varying 
amounts of expression plasmids including MyD88, TLR3, TLR4, IRAK4, RIP-1, 
IKKε, TRIF, TRAF3, FADD-DD (kind gifts from Prof. L. O’Neill, Trinity College 
Dublin, Ireland) and FADD (was a gift from Prof. A Winoto - Addgene plasmid 
31814), 3xAP1pGL3 (3xAP-1 in pGL3-basic) (a kind gift from Alexander Dent) 
(Addgene plasmid # 40342). Stimulations involving poly I:C were performed for 6 
hours prior to lysis of cells. Extracts were prepared by lysing the cells for 15 minutes 
in 50μl luciferase lysis buffer (10mM EDTA, 100mM DTT, 50% glycerol, 5% 
Triton X-100, 125mM Tris base, with pH adjusted to 7.8) and measured for Firefly 
luciferase and Renilla luciferase activity. Firefly luminescence readings were 
corrected for Renilla activity and expressed as fold stimulation over unstimulated 
empty vector (EV) control. Luminescent activity was then measured on Promega 
GloMax system (MSC). 
2.22 ELISA 
Supernatant from THP-1 macrophages stimulated with poly I:C +/- CH-11 for 48 
hours was used for IL-8 and IL-10 ELISA (BioLegend). A dilution of 1:1000 was 
necessary for IL-8 ELISA due to the copious amounts of IL-8 produced by this cell 
type. Samples for IL-10 ELISA required no dilution. ELISA was performed as per 
manufacturer’s instructions. IP-10/CXCL-10 protein analysis was performed using 
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MSD plates (Meso Scale Discovery, Washington DC, USA). A dilution of 1:20 was 
required due to the amount of IP-10/CXCL-10 produced by this cell type. MSD was 
performed as per manufacturer’s instructions. 
2.23 Virus Infection 
Sendai virus (SeV), a kind gift from Dr. Liam Fanning (Molecular Virology and 
Diagnostic Research Laboratory, UCC) was supplied at 10(7.5)CEID[50]/0.2 mL 
(ATCC). THP-1 macrophages were washed twice in PBS. Initial dilutions of SeV 
were performed, with a final dilution of 1:10,000 and 1:50,000 added to THP-1 
macrophages in a 1ml volume in full RPMI-1640 media. Cells were then incubated 
at 37
o
C for 5 hours, after which 1ml full media was added to each well. Cells were 
incubated for a further 3 hours, with lysis of cells performed, with total RNA 
extracted (Bioline) or for a total of 24 hours, with supernatant harvested for protein 
analysis by ELISA.  
2.24  Co-Immunoprecipitation 
Initial optimisation experiments were performed by transfecting HEK293T cells 
either 2μg or 4μg Flag-FADD and protein expression detected by Western blotting, 
immunoblotting using anti-Flag. Overexpression of VSV-TRIF was also performed 
using 1, 2, 4 and 10μg of VSV-tagged TRIF. Cells were lysed on ice for 1 hr in 1ml 
RIPA buffer (50mM Tris-HCL pH8.0, 150mM NaCl, 0.1% SDS, 0.5% Sodium 
deoxycholate, 1% Triton X-100, 1mM phenylmethylsulfonyl) supplemented with 
protease and phosphatase inhibitor cocktail. Cell scraping was performed, with 
samples collected into Eppendorf tubes. Samples were centrifuged at 14600rpm at 
4
o
C for 10 minutes. The resulting cell debris was discarded. An aliquot of the lysate 
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was removed for Western blotting of both VSV and Flag. Following optimisation, 
HEK293T cells were co-transfected with 2μg VSV-TRIF and 4μg Flag-FADD. 10μg 
Flag antibody or 10μg VSV antibody was added to 100μl protein A agarose beads 
and incubated overnight at 4
o
C with agitation. Protein A agarose beads complexed 
with the relevant antibody was added to lysate and incubated at room temperature for 
2hrs. Complex was washed x2 with TBS and x2 with RIPA buffer. Lysate-agarose 
bead suspension was then washed x1 in 500μl water, with 100μl Laemmli buffer 
added. Samples were then heated to 95
o
C for 5mins. Supernatant was then 
transferred to an Eppendorf and stored at -20
o
C. Samples then underwent 15% SDS-
PAGE gel electrophoresis and Western blotting. 
2.25 Precipitation of Endogenous Proteins 
THP1 cells were seeded and differentiated into macrophages as previously described 
(section 2.2) in 100mm dish at 1.5 x 10
6
 cells in 10mls of media, with cells 
stimulated as required. Cells were lysed on ice for 1 hr in 1ml RIPA buffer 
supplemented with protease and phosphatase inhibitor cocktail. Cell scraping was 
performed, with suspension collected into eppendorf tubes. Cells were centrifuged at 
14000 x g at 4
o
C for 10mins. The resulting cell debris was discarded. An aliquot of 
the lysate was removed for Western blotting of FADD. 4μg FADD antibody was 
added to protein A agarose beads and incubated overnight at 4
o
C with agitation after 
which lysate was added to this protein A agarose beads: FADD antibody complex , 
with immunoprecipitation performed as outlined for that of the co-
immunoprecipitation (section 2.24). 
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2.26 siRNA transfection of THP1 macrophages 
siRNA transfections were performed with Santa Cruz specific FADD siRNA (sc-
35352, Santa Cruz) and control siRNA (sc-37007, Santa Cruz). THP1 siRNA 
transfections were performed using the Amaxa (Lonza, Basel, Switzerland) system 
according to the manufacturer’s protocol. Cells were cultured for a further 48 hours 
prior to stimulation. 
2.27 Statistics 
Statistical Analysis was performed using GraphPad Prism software. Data are 
expressed as the mean ± SEM.  
Experiments were performed a minimum of three times in triplicate. Results were 
statistically evaluated using One-Way Anova with Tukeys post-test with MEF and 
iBMDM experiments assessed using Two-way Anova with student t-test. Values of 
p<0.001 are indicated by three asterisks (***). Values of p < 0.01 are indicated by 
two asterisks (**). Values of p < 0.05 are indicated by one asterisk (*).  
The results were considered to be significantly different at p values <0.05, with the 
significance indicated by a symbol such as asterisk as follows: *p<0.05, **p<0.01, 
***p<0.001. p>0.05 was considered non-significant.  
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Chapter 3: 
Investigating the role of Fas activation on 
immune responses. 
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3.1 Introduction 
Macrophages play a key role in the innate immune response. Detection of a viral 
infection by macrophages results in recruitment of a variety of immune cells to the 
site of infection. Initial detection is dependent on recognition by host Pattern 
Recognition Receptors (PRRs) (171). PRRs that detect viral infections include a 
group of structurally related cytosolic sensors including RIG-I-like receptors (RLRs), 
which are sensors of RNA, and AIM2-like receptors (ALRs), which are sensors of 
DNA. Detection of double-stranded RNA (dsRNA) by the cytosolic sensor RIG-I 
results in recruitment of its adapter protein IPS-1 (MAVS/Cardif/VISA) and the 
downstream induction of anti-viral cytokines (172). PRRs involved in the anti-viral 
immune response also include endosomally located Toll-Like Receptors (TLRs) 3, 
7/8 and 9, which recognise viral nucleic acids such as dsRNA, single-stranded RNA 
(ssRNA) and DNA, respectively (171, 173).  
Macrophages also express the Fas (CD95/Apo-1) receptor, which is a well-known 
member of the tumour necrosis factor (TNF) family (174). Whilst activation of Fas 
by ligation of its ligand, Fas ligand (FasL) is best studied in terms of its role in 
apoptosis, Fas activation has also been implicated in inflammation (151, 152). For 
instance, activation of the Fas signalling pathway has been shown to induce IL-18 
and IL-1β production in bone marrow derived macrophages (BMDMs) (151), and 
IL-8 production in THP1 macrophages(152). 
Following viral infection, both Fas and FasL have been shown to be induced across a 
number of different cell types. Co-expression of Fas and FasL in influenza infected 
HeLa cells resulted in Fas-mediated apoptosis of infected cells due to cell-cell 
interaction (175). Although co-expression of both Fas and FasL following Herpes 
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Simplex Virus (HSV)-2 infection of epithelial and keratinocyte cells was shown, 
apoptosis of these cells was not observed (164).  
As studies have demonstrated that Fas activation can result in production of pro-
inflammatory cytokines, and that viral infection can induce both Fas and FasL 
expression, the initial aim of the work presented in this chapter was to investigate the 
role of Fas in the induction of anti-viral cytokine and chemokine responses. As we 
observed little to no induction of anti-viral immune responses, we extended this 
study to investigate whether there was a potential role for Fas in modulating poly 
I:C-induced cytokine and chemokine responses. Work presented in this chapter 
demonstrates that activation of Fas modifies poly I:C-induced immune responses.  
3.2 Results 
3.2.1 Immunofluorescence staining shows expression of CD68, TLR3, Fas and 
FasL in THP1 macrophages and human monocyte derived macrophages 
(hMDMs). 
Phorbol 12-myristate 13-acetate (PMA) treated THP1 monocytes were differentiated 
into macrophages on glass slides over 3 days, (167) as per materials and methods. 
Human monocytes isolated from the peripheral blood of healthy volunteers were 
seeded onto glass slides and allowed to differentiate to macrophages over 7 days 
(167). CD68 is commonly used as a histological marker for cells of macrophage 
lineage. Consistent with this, positive staining of CD68 was observed following 
derivation of both THP1 monocytes and human peripheral blood mononuclear cells 
(PBMCs) into macrophages (figure 3.1a). Following this, we next determined that 
THP1 macrophages and hMDMs express the innate immune PRR TLR3, as well as 
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both Fas and FasL. Positive staining was observed for TLR3 (figure 3.1b), Fas 
(figure 3.1c) and FasL (figure 3.1d) in both THP1 macrophages and hMDMs. 
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Figure 3.1: THP-1-derived macrophages and human monocyte-derived 
macrophages (hMDMs) express CD68, TLR-3, Fas, and Fas Ligand (FasL). 
THP-1 cells were differentiated with 100μg/ml PMA for 72 hrs. Human monocyte-
derived macrophages were differentiated into macrophages over 7 days on glass 
slides. Florescent images indicate positive staining for the myeloid marker CD68 
(green) (a), the PRR TLR-3 (red) (b), Fas (red) (c) and FasL (red) (d) superimposed 
with nuclear staining using DAPI (blue). Bars, 50μm. Data are representative of 
three individual experiments. 
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3.2.2 Stimulation with poly I:C increases expression of Fas and FasL by 
macrophages. 
As previous studies have demonstrated that viral infection resulted in increased Fas 
and FasL expression in macrophages (175, 176), we initially confirmed that the 
dsRNA mimetic poly I:C could up-regulate both Fas and FasL in THP1 
macrophages. Upon stimulation with increasing concentrations of poly I:C, THP1 
macrophages showed increased expression of both Fas and FasL at both the mRNA 
(figure 3.2a, b) and protein level (figure 3.2c). 
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Figure 3.2: Fas and Fas Ligand expression are increased following treatment 
with increasing concentrations of poly I:C. THP-1 cells were differentiated with 
100μg/ml PMA for 72 hrs. Cells were treated with increasing concentrations of poly 
I:C (5, 10, 20 and 40µg/ml). Fas and FasL expression was detected by qRT-PCR 
after 8 hrs (a,b) with cells normalised to GAPDH expression levels. mRNA is 
expressed relative to untreated cells. Western blotting was performed 48 hrs (c). 
Results shown representative of three separate experiments. ** p<0.01, values shown 
as Mean ± SEM, (n=3). 
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3.2.3 Stimulation with agonistic anti-Fas antibody (CH11) does not affect either 
TLR3 or RIG-I expression. 
As we have demonstrated that poly I:C can induce expression of both Fas and FasL, 
we next investigated the effect of Fas activation on the expression levels of innate 
immune receptors involved in viral recognition; TLR3 and RIG-I. THP1 
macrophages were stimulated with increasing concentrations of the agonistic anti-
Fas antibody CH11, with expression of both TLR3 and RIG-I mRNA determined. 
We observed no induction of TLR3 (figure 3.3a) or RIG-I (figure 3.3b) mRNA 
expression following 8 hours stimulation, suggesting that crosstalk, in terms of 
receptor expression levels between these pathways is unidirectional.   
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Figure 3.3: Stimulation with agonistic anti-Fas (CH11) did not alter either 
TLR-3 or RIG-I expression in THP-1 macrophages. THP-1 cells were 
differentiated with 100μg/ml PMA for 72 hrs. Cells were treated with increasing 
concentrations of CH11 (25, 50, 100 and 200ng/ml) for 8 hours following which 
qRT-PCR was performed. mRNA expression was normalised to GAPDH expresion 
levels. mRNA expression of  TLR-3 (a) and RIG-I (b) are expressed relative to 
untreated cells. Values are shown as Mean ± SEM, (n=3) with results shown 
representative of three separate experiments. 
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3.2.4 Caspase 3/7 activation was not induced following Fas activation or poly 
I:C stimulation in THP1 macrophages. 
Given the well characterised apoptotic function of Fas, we next investigated whether 
induction of Fas and FasL expression by poly I:C induced apoptosis in THP1 
macrophages by measuring caspase 3/7 activation. Stimulation of THP1 
macrophages with either poly I:C or CH11 did not result in enhanced caspase 3/7 
activation (figure 3.4a). This is consistent with previous studies, whereby activation 
of Fas in THP1 macrophages also did not trigger apoptotic cell death (152). To 
confirm that CH11 was able to induce apoptosis in Fas sensitive cells, Jurkat T cells 
were treated with CH11 which resulted in strong caspase 3/7 activation (figure 3.4a). 
Cell viability of THP1 derived macrophages was also unaffected by either poly I:C 
or CH11 treatment (figure 3.4b). In contrast, staurosporine reduced the viability of 
the cells. Together, these data demonstrates that Fas activation with and without poly 
I:C stimulation does not induce caspase 3/7 activation, nor does it affect cell 
viability, despite increased Fas and FasL expression observed on poly I:C stimulated 
THP1 macrophages.  
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Figure 3.4: Caspases 3/7 activation and cell viability were unaffected by both 
poly I:C and CH11 stimulation. THP-1-derived macrophages and Jurkat T cells 
were treated with 200ng/ml CH11 and/or 20μg/ml poly I:C for 24 hrs, or with 5 μM 
staurosporine as indicated. Caspase 3/7 activity (a) was measured by fluorescence 
whereby the amount of caspase 3/7 activity is directly proportional to the amount of 
fluorescence measured. Cell viability (b) was determined by trypan blue exclusion 
after 24 hours. Data shown are representative of three independent experiments, with 
values shown as percentage Caspase 3/7 activation relative to Jurkat T cells 
stimulated with 200ng/ml CH11 (a) or as Mean ± SEM (b).  
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3.2.5 Fas activation does not induce significant inflammatory cytokine or 
chemokine production in THP1 macrophages.   
As expression of both Fas and FasL were both augmented by poly I:C, we next 
investigated the ability of macrophages to produce cytokines and chemokines in 
response to Fas activation by the agonistic Fas antibody CH11 (figure 3.5). Initially 
we focused on induction of anti-viral response genes such as IFNβ and IP-10. 
Interestingly, we observed no up-regulation of these genes in response to Fas 
activation (figure 3.5a). As some previous studies have shown that Fas activation can 
up-regulate expression of other pro-inflammatory cytokines, we next examined 
expression of IL-8 and TNFα. Similar to results obtained with IP-10 and IFNβ, up-
regulation of these cytokines was not observed (figure 3.5b). To confirm that the 
concentration of CH11 used was capable of inducing cytokine expression, SW480 
intestinal epithelial cells were stimulated with CH11 and cytokine production 
assessed. In contrast to THP1 macrophages, Fas activation by CH11 in SW480 cells 
resulted in a strong induction of IP-10, IL-8 and TNFα (figure 3.5c).   
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Figure 3.5: Fas activation does not induce significant inflammatory cytokine 
production in THP-1 macrophages. THP-1 macrophages (a, b) and SW480 cells  
(c) were treated with 200ng/ml CH11 for 8 hrs. Changes in cytokine expression were 
detected by qRT-PCR. mRNA expression was normalised to GAPDH expression 
levels, with changes in mRNA expressed relative to untreated cells. qRT-PCR values 
are shown as Mean ± SEM, (n=3), * p<0.05, ** p<0.01 and *** p<0.001. 
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3.2.6 Fas activation reduces poly I:C-induced TNFα, IL-10, IL-8 and IFNβ 
mRNA production in THP1 macrophages. 
Given that poly I:C was able to increase the expression of both Fas and FasL, but 
that no augmentation in anti-viral response genes was observed upon Fas activation, 
we next investigated whether CH11 stimulation could affect poly I:C-induced 
cytokine production. Stimulation of THP1 macrophages with poly I:C alone induced 
expression of IFNβ, IL-8, IL-10 and TNFα. However, Fas activation with subsequent 
poly I:C stimulation resulted in a reduction in the expression of all four cytokines. 
Poly I:C-induced IFNβ, IL-10 and TNFα production were significantly reduced by 
50% by Fas activation  (figure 3.6a, c, d). A reduction in IL-8 production was also 
observed, albeit to a lesser extent (figure 3.6b). 
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Figure 3.6: Fas activation decreases poly I:C-induced IL-8, IL-10, TNFα and 
IFNβ transcription. THP-1-derived macrophages were treated with 200ng/ml CH11 
for 1 hr followed by stimulation with 20μg/ml poly I:C. mRNA expression was 
normalised to GAPDH, with changes in IFNβ (a), IL-8 (b), IL-10 (c) and TNFα (d) 
expressed relative to untreated cells. Data shown are a combination of three 
independent experiments, with values shown as Mean ± SEM. * p<0.05, ** p<0.01. 
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3.2.7 Poly I:C-induced IP-10 mRNA production is augmented following Fas 
activation. 
As our initial aim had been to investigate the role of Fas in anti-viral response, we 
also examined expression of IP-10 (CXCL-10), a potent T cell chemokine. In 
contrast to other cytokines examined, poly I:C-induced IP-10 production was 
significantly augmented (3 fold; p <0.01) by Fas activation with CH11 (figure 3.7), 
suggesting that Fas activation plays a role in enhancing poly I:C-induced IP-10 
production. 
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Figure 3.7: Fas activation augments poly I:C-induced IP-10 transcription. THP-
1-derived macrophages were treated with 200ng/ml CH11 for 1 hr followed by 
stimulation with 20μg/ml poly I:C. IP-10 mRNA expression was detected by qRT-
PCR at 8 hrs with mRNA normalised to GAPDH. Changes in IP-10 expression were 
expressed relative to untreated cells. Data shown are a combination of three 
independent experiments, with values shown as Mean ± SEM. ** p<0.01. 
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3.2.8 Fas activation reduces poly I:C-induced IL-8 and IL-10 protein 
expression, but augments IP-10 protein expression in THP1 macrophages. 
To confirm mRNA analysis, changes in IL-8, IL-10, TNFα and IP-10 protein 
production were detected by ELISA. THP1 macrophages were stimulated as outlined 
in the figure legend (figure 3.8), with supernatant harvested and ELISA analysis 
performed. Similar to results shown in figures 3.6 and 3.7 for mRNA expression, 
CH11 did not induce IL-8, IL-10, TNFα and IP-10 cytokine production (figure 3.8). 
However, Poly I:C-induced IL-8 production was reduced by 30% by Fas activation 
(figure 3.8a), while poly I:C-induced IL-10 production was reduced to that of 
untreated levels by Fas activation (figure 3.8b). In contrast to the mRNA data 
obtained, poly I:C-induced TNFα production was unchanged by pre-treatment with 
CH11 (figure 3.8c). Poly I:C-induced IP-10 production, however, was again 
significantly augmented (p <0.001) by Fas activation (figure 3.8d). 
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Figure 3.8: Fas activation decreases poly I:C-induced IL-8, IL-10 and TNFα 
protein production, whilst augmenting IP-10. THP-1-derived macrophages were 
treated with 200ng/ml CH11 for 1 hr followed by stimulation with 20μg/ml poly I:C. 
Changes in IL-8 (a), IL-10 (b), TNFα (c) and IP-10 (d) protein production were 
detected by ELISA after 48 hrs. Data shown are a combination of three independent 
experiments, with values shown as Mean ± SEM. * p<0.05, *** p<0.001. 
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3.2.9 Fas activation reduces poly I:C-induced TNFα, IL-10 and IFNβ mRNA 
production, while augmenting poly I:C-induced IP-10 mRNA production in 
human monocyte-derived macrophages.  
As we had observed that Fas activation could modulate poly I:C-induced cytokine 
production in THP1 cells, we wished to confirm this result in a primary cell line. 
Fresh whole blood was obtained from healthy volunteers. Peripheral blood 
mononuclear cells (PBMCs) were then isolated, with monocytes derived into 
macrophages for 7 days. Similar to THP1 macrophages, Fas activation did not 
significantly induce IFN IL-10, TNFor IP-10 cytokine expression (figure 3.9). 
Both poly I:C-induced expression of  IFN and TNFwere reduced by 50% upon 
co-stimulation with CH11(figure 3.9a, c), while poly I:C-induced IL-10 production  
was reduced by 40% by Fas activation (figure 3.9b). However, poly I:C-induced P10 
production was again augmented upon Fas activation (figure 3.9d).  
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Figure 3.9: Fas activation decreases poly I:C-induced IFNβ, IL-10 and TNFα 
whilst augmenting production of IP-10 cytokine production in hMDMs. Human 
monocyte-derived macrophages were treated with 200ng/ml CH11 for 1 hr followed 
by stimulation with 20μg/ml poly I:C. mRNA expression was detected by qRT-PCR 
after 8 hrs and normalised to GAPDH. Changes in IFNβ (a), IL-10 (b), TNFα (c) and 
IP-10 (d) are expressed relative to untreated cells. Data shown are a combination of 
three independent experiments, with values shown as Mean ± SEM. * p<0.05, ** 
p<0.01, *** p<0.001. 
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3.2.10 Poly I:C-induced IP-10 production in THP1 macrophages was unaffected 
when pre-stimulated with the IgM isotype control. 
To ensure that modulation of cytokine expression observed following stimulation of 
Fas with CH11 is specific to Fas activation, we next stimulated cells with a non-
specific isotype IgM control antibody. IgM stimulation alone had no effect on IP-10 
production. Poly I:C stimulation strongly induced IP-10 mRNA expression, which 
was unaffected by stimulation with the IgM isotype control (figure 3.10). 
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Figure 3.10: Poly I:C-induced IP-10 production was unchanged by stimulation 
with IgM isotype control. THP-1 macrophages  were treated with 200ng/ml IgM 
isotype control for 1 hr followed by stimulation with 20μg/ml poly I:C. mRNA 
expression were detected by qRT-PCR after 8 hrs and normalised to GAPDH. 
Changes in IP-10 mRNA expression are expressed relative to untreated cells. Data 
shown are a combination of three independent experiments, with values shown as 
Mean ± SEM, ns – no significant change observed. 
 
 
 
 
  
85 
 
3.2.11 Pre-treatment of macrophages with CH11 modulates both Sendai Virus 
(SeV) and poly A:U-induced cytokine production. 
As poly I:C is recognised by both TLR3 and RIG-I, we next investigated which of 
these receptors was involved in the altered cytokine production seen upon Fas 
activation by CH11 and subsequent poly I:C stimulation. We initially investigated 
the effect of CH11 stimulation on SeV-induced cytokine production. SeV is a 
negative sense single-stranded RNA virus which signals specifically through the 
receptor RIG-I. SeV induced robust expression of IP-10 (figure 3.11a and b). Similar 
to data observed following co-stimulation with poly I:C and CH11, SeV-induced IP-
10 mRNA expression was significantly augmented by Fas ligation (2 fold; p <0.05) 
(figure 3.11a). Similarly, SeV-induced IP-10 protein production was also 
significantly increased by Fas ligation (2 fold; p <0.01), compared with SeV-induced 
IP-10 protein production alone (figure 3.11b).  
SeV-induced IL-8 expression was also examined, with SeV-induced IL-8 mRNA 
expression increased (2 fold). Unlike previous results obtained whereby CH11 
reduced poly I:C-induced cytokine production, the induction of IL-8 mRNA or 
protein by SeV was unchanged when pre-stimulated with CH11 (figure 3.11c and d).  
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Figure 3.11: Ligation of macrophages with CH11 increases SeV-induced IP-10 
production.THP-1-derived macrophages were treated with 200ng/ml CH11 for 1 hr 
followed by infection with Sendai virus. mRNA expression was determined by qRT-
PCR after 8 hrs and normalised to GAPDH with changes in IP-10 and IL-8 
production expressed relative to untreated cells (a, c). Changes in expression of IP-
10 and IL-8 were also detected by ELISA after 48 hrs (b, d). Data shown are 
representative of three independent experiments, with values shown as Mean ± SEM. 
* p<0.05, ** p<0.01  
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To further investigate through which receptor modulation of poly I:C-induced IP-10 
production by CH11 is mediated, we next used the TLR3 specific agonist, poly A:U. 
While CH11 did not induce significant levels of IP-10 cytokine production, poly 
A:U stimulation of THP1 macrophages resulted in an increase of IP-10 mRNA 
production. Fas activation by CH11 with subsequent poly A:U stimulation resulted 
in augmentation of IP-10 production (2.5 fold; p <0.01) compared to poly A:U alone 
(figure 3.12a), suggesting that Fas activation is required for enhanced TLR3 
mediated IP-10 production. The effect of Fas ligation on poly A:U-induced IFNβ 
expression was also examined. Poly A:U stimulation resulted in a 2 fold increase of 
IFNβ production in THP1 macrophages. Although co-stimulation with CH11 did not 
significantly affect IFNβ production, a downward trend was observed (figure3.12b). 
 
  
 
 
88 
 
 
 
Figure 3.12: The augmentation in poly I:C-induced IP-10 production following 
ligation of Fas is also mediated by TLR3. THP-1-derived macrophages were 
treated with 200ng/ml CH11 for 1 hr followed by stimulation with poly A:U. mRNA 
expression was determined by qRT-PCR after 8 hrs and normalised to GAPDH with 
changes in IP-10 (a) and IFNβ (b) expressed relative to untreated cells. Data shown 
are a combination of three independent experiments, with values shown as Mean ± 
SEM. ** p<0.01  
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Taken together, this data indicate that the ability of CH11 to modulate poly I:C-
induced cytokine production may occur through an interaction with the RIG-I and 
TLR3 signalling pathways. 
3.2.12 Poly I:C-induced IP-10 production was augmented in immortalised bone 
marrow derived macrophages (iBMDMs), with no augmentation observed in 
TRIF
-/-
 iBMDMs. 
No report has previously implicated cross-talk between the TLR3 pathway and the 
Fas signalling pathway. As we have demonstrated that poly I:C enhances both Fas 
and FasL expression, we wished to further investigate potential cross-talk between 
the TLR3 and Fas signalling pathways. Therefore, we examined the effect of Fas 
activation on poly I:C-induced IP-10 production in immortalised wild type bone 
marrow-derived macrophages (iBMDMs), and iBMDMs lacking the TLR3 adapter 
protein TRIF (TRIF
-/-
 iBMDMs). Consistent with our data using the human agonistic 
Fas antibody CH11, stimulation of Fas with the murine agonistic Fas antibody, Jo2, 
significantly augmented poly I:C-induced IP-10 production by wild type iBMDMs 
(p <0.001) (figure 3.13) . This is noteworthy as we have now observed augmented 
poly I:C-induced IP-10 production by Fas activation in three different cell lines, 
indicating this is not a cell line specific effect. In contrast, no augmentation of poly 
I:C-induced IP-10 production was observed in the TRIF
-/-
 iBMDMs by Fas 
activation (figure 3.13). This data provides further evidence that the ability of Fas to 
augment poly I:C induced IP-10 production involves the TLR3 signalling pathway. 
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Figure 3.13: Poly I:C-induced IP-10 production is augmented following Fas 
activation in wild-type immortalised bone marrow-derived macrophages 
(iBMDMs), which was absent from TRIF-/- iBMDMs. Immortalised wild type 
and TRIF-/- BMDMs were stimulated with 1ng/ml murine agonistic Fas antibody 
(Jo2) for 1 hr followed by stimulation with 20μg/ml poly I:C for a further 8 hrs. 
mRNA expression was detected by qRT-PCR and normalised to GAPDH. Changes 
in IP-10 were expressed relative to untreated cells. Data shown are representative of 
three independent experiments, with values shown as Mean ± SEM. ***p<0.001 
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3.2.13 Optimal poly I:C-induced IP-10 production by Fas activation occurs 
between 4 and 8 hours.  
IP-10 is an early phase potent T cell chemokine. As a result, we next wished to 
determine the time-frame by which poly I:C-induced IP-10 expression is augmented 
by Fas ligation. IP-10 production was examined over a 24 hour time-course in the 
presence or absence of CH11. In contrast to all other time points, CH11 was seen to 
induce IP-10 mRNA at 4 hours of stimulation to a level comparable to that of poly 
I:C. However, the level of poly I:C-induced IP-10 following Fas ligation was 
dramatically increased compared to poly I:C alone (75 fold) (figure 3.14a). Poly I:C-
induced IP-10 production following Fas ligation was also increased at 8 hours (3 
fold) and at 12 hours (1.5 fold), compared to poly I:C alone (figure 3.14b and c 
respectively). In contrast to 4, 8 and 12 hours, poly I:C-induced IP-10 production 
following Fas ligation was reduced at 24 hours (50% reduction) (figure 3.14d). This 
data suggests that the ability of CH11 to modulate poly I:C-induced IP-10 
production is an early event with maximum augmentation observed at 4 hours, an 
effect which is reversed by 24 hours. 
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Figure 3.14: Poly I:C-induced IP-10 production is augmented following Fas 
activation at 4, 8 and 12 hrs with reduction in IP-10 production at 24 hrs. THP-1 
macrophages were stimulated with 200ng/ml CH-11 for 1 hr followed by poly I:C 
stimulation with 20μg/ml for 4 hrs (a), 8 hrs (b), 12 hrs (c) and 24 hrs (d). Cytokine 
expression was detected by qRT-PCR and normalised to GAPDH. Changes in 
cytokine expression were expressed relative to untreated cells. 
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3.2.14 Stimulation of THP1 macrophages with CH11 and poly I:C results in 
enhanced Jurkat T cell recruitment and increased CXCR-3 expression.  
We have demonstrated that IP-10 production is enhanced in THP1 macrophages 
stimulated with both CH11 and poly I:C. As IP-10 is a potent T cell chemokine, we 
next investigated what effect this would have on T cell recruitment. Optimisation 
experiments were initially performed. Increased migration of Jurkat T cells towards 
RPMI-1640 media supplemented with 10% serum and IP-10 was observed compared 
to media supplemented with 10% serum alone (figure 3.15a). Next, supernatant from 
THP1 macrophages treated with poly I:C in the presence and absence of CH11 for 
24 hours was harvested and migration of Jurkat T cells towards these supernatants 
assessed using a transwell migration assay. We were unable to obtain consistent 
results for this assay due to a high variation between experiments, resulting in large 
error bars (figure 3.15 b). Therefore, we next performed a cell recruitment 
experiment, examining the recruitment of Jurkat T cells to THP1 macrophages which 
were stimulated with poly I:C with and without CH11 stimulation for 24 hours prior 
to addition of Jurkat T cells (figure 3.15 c-f). Recruitment and attachment of Jurkat T 
cells to these macrophages was then examined following 24 hours of co-culture. We 
observed that both untreated and CH11 stimulated THP1 macrophages had minimal 
T cell recruitment and attachment, as determined by the number of T cells 
surrounding macrophages (figure 3.15 c, d), while enhanced recruitment of T cells 
was observed following stimulation of THP1 macrophages with poly I:C (figure 3.15 
e). Co-stimulation with both Fas and poly I:C increased T cell recruitment (figure 
3.15 f). This data is also represented graphically, whereby we calculated the ratio of 
T cells attached to macrophages to T cells not attached to macrophages (figure 3.15 
g) for all stimulations. 
94 
 
 
Figure 3.15: THP-1 macrophages stimulated with both poly I:C and CH11 had 
enhanced Jurkat T cell recruitment compared to other treatment groups. Jurkat 
T cells were added to the upper well of a transwell and migration towards complete 
media and complete media with 50ng IP-10 determined (a). Migration of Jurkat T 
cells towards supernatant harvested from THP-1 macrophages treated with poly I:C 
with and without CH11 was also determined (b). After 2 hrs, migrated cells were 
collected, stained with crystal violet and absorbance measured (a, b). THP-1 
macrophages were treated with 200ng/ml CH11 for 1 hr, followed by 20μg/ml poly 
I:C for 24hrs. Jurkat T cells were added to treated macrophages and cultured for 24 
hrs, with cell aggregation observed microscopically. Macrophages are outlined in 
black, with Jurkat T cells outlined in red (c, d, e, f). The ratio of T cells attached to 
macrophages : non-attached T cells was determined with a minimum of 18 visual 
fields counted (g). Data shown are representative of three independent experiments.  
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As we had observed increased poly I:C-induced IP-10 production following Fas 
activation, and also increased recruitment of T cells to macrophages following co-
stimulation of cells with poly I:C and CH11, we next wished to determine if 
enhanced expression of the IP-10 receptor, CXCR-3, on Jurkat T cells may account 
for the increased recruitment of T cells to treated THP1 macrophages. Resting Jurkat 
T cells expressed low levels of CXCR-3 (4.1%) (figure 3.16a). THP1 macrophages 
were either untreated or stimulated with poly I:C, CH11, or co-stimulated with both 
poly I:C and CH11 for 24 hours. Supernatant was then harvested and used for sub-
culturing of Jurkat T cells. CXCR-3 expression increased 10-fold upon culturing of 
T cells in untreated THP1 macrophage supernatant (figure 3.16b). Whilst culturing 
of T cells in macrophage supernatant with CH11 (figure 3.16c) resulted in only a 
modest augmentation of CXCR-3 expression on T cells above unstimulated, most 
augmentation in CXCR-3 expression was observed following stimulation with poly 
I:C and CH11 (figure 3.16e). Taken together, these results suggest optimal T cell 
recruitment of T cells to IP-10 requires induction of CXCR-3 expression on T cells 
by an as of yet unknown macrophage-derived factor. These studies also show that 
augmented IP-10 production seen upon co-stimulation of macrophages with poly I:C 
and CH11 may have a functional consequence regarding increased recruitment of T 
cells to macrophages.  
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Figure 3.16: The IP-10 receptor, CXCR-3, is induced by untreated macrophage 
supernatant and increased by a combination of poly I:C and CH-11. Jurkat T 
cells were cultured in RPMI-1640  media (a), or in macrophage-derived supernatant 
which was either untreated (b) or treated with (c) 200ng/ml CH11, (d) 20ug/ml poly 
I:C or (e) poly I:C and CH11 for 24 hrs. Expression of CXCR-3 was determined by 
flow cytometry. Data are representative of three individual experiments.  
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3.3 Discussion 
Our findings in this study demonstrate that activation of the Fas signalling pathway 
by ligation of Fas to its ligand, FasL, modulates poly I:C-induced inflammatory 
cytokine production. We have demonstrated augmentation of Fas and FasL 
expression in response to poly I:C stimulation of THP1 macrophages. We have also 
showed that poly I:C-induced production of IFNβ, IL-8, IL-10 and TNFα were 
reduced upon activation of Fas. Conversely, we have shown that poly I:C-induced 
IP-10 production is augmented by Fas activation, with caspase 3/7 activation 
unaffected. We also observed enhanced CXCR-3 expression on Jurkat T cells when 
cultured in THP1 macrophage supernatant. Finally, we observed increased T cell 
recruitment towards THP1 macrophages treated with poly I:C and CH11, compared 
to poly I:C alone.  
We have demonstrated increased Fas and FasL expression following poly I:C 
stimulation in THP1 macrophages. Previous studies have also demonstrated 
increased Fas expression following exposure to other pathogen-associated membrane 
proteins (PAMPs). Lipopolysaccharide (LPS) has been shown to enhance Fas 
expression in bone marrow-derived macrophages (BMDMs) (151). Similarly, the 
double-strand RNA mimetic, poly I:C, has been shown to enhance Fas expression in 
the murine macrophage cell line, RAW 264.7 (176). Consistent with this, viral 
proteins have also been shown to enhance both Fas and FasL expression. Basal FasL 
expression on human monocyte-derived macrophages was enhanced following HIV 
(human immunodeficiency virus) infection (177), while influenza was also shown to 
induce expression of both Fas and FasL in HeLa cells (175). Given that we too have 
observed enhanced Fas and FasL expression following stimulation with poly I:C, our 
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findings add further evidence that Fas and FasL can be increased by TLR and viral 
stimuli. 
Fas and FasL are best known for inducing apoptosis. Whilst we have demonstrated 
increased Fas and FasL expression following poly I:C stimulation, we did not detect 
any change in cell viability, nor did we see activation of the executioner caspases, 
caspases-3/7. Measurement of caspase-3/7 activation was used as a marker of 
apoptosis in this study, as activation of caspase-3 results in irreversible commitment 
to apoptosis of the cell (178). Indeed, some viruses target the Fas apoptotic pathway, 
thereby inducing apoptosis (179, 180). Similar to our findings however, studies have 
also demonstrated that viral infection does not consistently induce Fas mediated-
apoptosis. The DNA virus, equine herpesvirus type 2 (EHV-2) can bind to the pro-
domain of caspase-8 (163), while the DNA virus molluscum contagiosum virus 
(MCV) binds to FADD, thus preventing Fas mediated apoptosis (163). Moreover, 
although Herpes Simplex Virus 2 (HSV-2) Fas and FasL expression in keratinocytes 
and epithelial cells, increased levels of the anti-apoptotic protein Bcl-2 was also 
observed in HSV-2 infected cells, protecting the infected cells, and thus the virus, 
from Fas-mediated apoptosis (164). We too observed increased Fas and FasL 
expression following poly I:C stimulation of THP1 macrophages with no caspase 3/7 
activation, and this may be due to enhanced levels of the anti-apoptotic proteins 
cFLIP or Bcl-2. However, the mechanisms responsible for resistance to Fas-
mediated apoptosis were not investigated as part of this study. Taken together, these 
studies suggests that the up-regulation of Fas and FasL observed may play an 
alternative function, possibly in host defense against some viral infections.  
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As we observed increased Fas and FasL expression following poly I:C stimulation in 
THP1 macrophages, and several studies have now described a variety of non-
apoptotic functions for Fas including migration, proliferation and inflammation, we 
next investigated the effect of Fas activation on inflammatory cytokine production 
by THP1 macrophages. Previous studies have demonstrated that Fas activation 
induced IL-18 and IL-1β production in macrophages (151). However, we did not see 
any induction of cytokine production upon Fas ligation. This may have been due to 
the concentration of CH11 used as in another study which used a similar 
concentration of CH11, cytokine production in THP1 cells was also not observed. 
Increasing the concentration of CH11 however, resulted in the induction of IL-8 to a 
level similar to that seen upon LPS stimulation (152). As poly I:C-induced both Fas 
and FasL expression, with no induction of cytokines or chemokines following Fas 
activation, we hypothesised that Fas may be modulating poly I:C-induced cytokine 
and chemokine production.    
We have demonstrated that Fas ligation is capable of modulating poly I:C-induced 
cytokine production through both the RIG-I and TLR3 pathways, with specific 
enhancement of IP-10. Whilst no study to date has examined the effect of Fas 
ligation on poly I:C signalling, studies have demonstrated that the Fas signalling 
pathway plays a role in modulating TLR4 and LPS responses (162, 176, 181). LPS-
induced IL-6 production was reduced upon interruption of Fas ligation, with reduced 
LPS-induced IL-6 production seen in both Fas (lpr) and FasL (gld) deficient mice,
 
compared to wild-type mice (181). Consistent with this, blocking of Fas-FasL 
interaction in two models of cardiac dysfunction was shown to attenuate 
inflammatory cell infiltration and cytokine secretion in the myocardium without 
affecting apoptosis in vivo (161, 162), significantly preserving cardiac function. 
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Additionally Fas ligation on macrophages promoted TLR4-mediated chronic 
inflammation in a model of collagen-induced arthritis (181). These studies illustrate 
the importance of the Fas signalling pathway in TLR4 mediated signalling. Given 
our findings that the Fas signalling pathway also plays a role in signalling through 
both RIG-I and TLR3 pathways, our data indicates that the cross-talk between Fas 
and pathogen recognition receptors is more extensive than previously thought. 
IP-10 is an early response gene; therefore we investigated the time-frame for the 
augmentation in IP-10 production. The augmentation in IP-10 following activation 
with both poly I:C and agonistic anti-Fas was most dramatic at the earlier time points 
of 4 and 8 hours, with reduced augmentation observed at 12 hours. A reduction in 
poly I:C-induced IP-10 occurred at 24 hours was seen following co-activation of 
both receptors. Changes in the expression levels of the receptors may account for this 
divergent effect at 24 hours as it is well-known that Fas is internalised following 
activation (181). Alternatively it is possible that Fas ligation is primarily required for 
up-regulation of IP-10 production in the early phase of the anti-viral response, 
consistent with the high level of IP-10 observed at 4 hours compared to 24 hours.  
IP-10 is a potent T cell chemokine which affects T cell generation and trafficking in 
vivo (174), recruiting T cells expressing its receptor CXCR-3 (182, 183). While we 
have shown a specific enhancement of IP-10 by Fas activation and poly I:C 
stimulation, we have also shown that expression of the IP-10 receptor, CXCR-3 in 
Jurkat T cells is increased upon culturing in macrophage-derived supernatant, 
suggesting that Fas activation may play a significant role in IP-10 production 
following viral infection. The importance of IP-10 in clearance of viral infection is 
well established (174, 184, 185). IP-10 has been shown to protect mice infected with 
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neurotropic coronavirus mouse hepatitis (MHV), as blocking of IP-10 production 
increased mouse death and reduced the ability of infected mice to clear the infection 
(184). Moreover, mice lacking Fas or FasL showed reduced IP-10 production 
following infection with herpes simplex virus (HSV)-2, with a reduction in immune 
cell recruitment resulting in delayed clearance of the virus (186). We have also 
demonstrated increased T cell recruitment and attachment towards macrophages 
treated with poly I:C and CH11 compared to other treatment groups. Taken together, 
these studies demonstrate the importance of both IP-10 production and the Fas 
signalling pathway in protecting the host following viral infection. 
Excessive IP-10 production however, has implications for a variety of human 
diseases including infectious diseases, chronic inflammation, immune dysfunction, 
tumour development, metastasis and dissemination (182). Increased IP-10 
production may exacerbate inflammation and induce significant tissue damage as a 
result of increased immune cell trafficking (187). It is important, therefore, that 
following viral infection, IP-10 levels are regulated to ensure an adequate immune 
response whilst avoiding an exacerbated inflammatory response. It has been 
demonstrated that RNA derived from necrotic synovial fluid cells induces IP-10 
expression by rheumatoid arthritis synovial fibroblasts, potentially by activation of 
TLR3 (188). The majority of T cells present in the synovial fluid of joints affected 
by rheumatoid arthritis (RA) are positive for the IP-10 receptor CXCR-3 (189, 190), 
with an increase in IP-10 chemotactic gradient favouring migration of CXCR-3 
positive T cells from the serum to synovium of RA affected joints (189).  As 
activated T cells express FasL, our results suggest that in situations of excessive T 
cell recruitment as characterised by many chronic inflammatory conditions, binding 
of FasL expressed by T cells to macrophage-expressed Fas may result in activation 
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of Fas, which may further exacerbate the inflammatory response. Therefore, 
blocking Fas may represent a potential therapeutic target for pathologies requiring T 
cell involvement, such as rheumatoid arthritis (189-191) and more recently systemic 
lupus erythematosus (SLE) (192).  
In conclusion, we have shown that the chemokine IP-10 is specifically enhanced 
following Fas activation and subsequent stimulation with poly I:C, poly A:U and 
SeV, and that the ability of Fas to modulate poly I:C-induced cytokine production is 
not specific to either TLR3 or RIG-I, but is rather common to both pathways. This 
indicates that Fas ligation will affect cytokine production in response to a myriad of 
viral infections.  
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Chapter 4 
Identification of a mechanism by which Fas 
activation augments poly I:C-induced IP-10 
production. 
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4.1 Introduction 
Fas is a well characterised death receptor, with ligation of Fas by its ligand, FasL, 
resulting in the recruitment of the adaptor protein Fas-associated death domain 
(FADD). FADD contains two functional domains, the Death Effector Domain 
(DED) and the Death Domain (DD), with binding of FADD to Fas by DD-DD 
interaction. This in turn recruits the cysteine protease pro-caspase-8 via a DED-DED 
interaction, resulting in the formation of the death-inducing signalling complex or 
DISC. Following activation in the DISC, caspase-8 in turn activates the effector 
caspases, culminating in the apoptotic cell death of sensitive cells (193). As 
mentioned in the previous chapter, the Fas signalling pathway, together with its 
adaptor protein FADD, can also mediate other biological processes. FADD has been 
shown to be essential for embryonic development in utero (102). FADD has also 
been shown to have a functional role in processes such as autophagy and apoptosis, 
tumour growth, necrosis and innate immunity (194).  
In the previous chapter, we demonstrated that Fas activation augmented both TLR3 
and RIG-I induced IP-10 production. While a role for FADD in dsRNA-induced type 
I interferon (IFN) production through the RIG-I signalling pathway has been 
demonstrated (165), the role of FADD in TLR3-induced cytokine production is 
unclear. IP-10/CXCL-10 is a potent chemokine, recruiting immune cells such as Th1 
cells and Natural Killer (NK) cells expressing its receptor, CXCR-3 (182). IP-10 
plays an important role in viral clearance (174, 184, 185). However, dysregulation of 
IP-10 production has been implicated in a variety of pathologies (182, 187). It is 
important, therefore, that following viral infection, IP-10 levels are regulated to 
ensure an adequate immune response whilst avoiding an exacerbated inflammatory 
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response. Thus, identifying mechanisms involved in regulating IP-10 production in 
response to viral infection is important. The aim of the current chapter was to 
investigate the mechanism involved in the augmentation of poly I:C-induced IP-10 
production by Fas and to characterise the role of the Fas adapter FADD in this 
pathway.    
4.2 Results 
4.2.1 Attempt at optimising siRNA knockdown of FADD expression in THP1 
macrophages.      
In the first chapter we identified a role for Fas in modifying poly I:C-induced 
cytokine production with specific upregulation of IP-10. Given the important role of 
FADD in the Fas signalling pathway, we next wished to analyse the role of FADD in 
poly I:C-induced IP-10. We initially aimed to investigate the role of FADD in poly 
I:C-induced IP-10 production by reducing endogenous levels of FADD by siRNA 
transfection. THP1 cells were transfected with FADD-specific siRNA or scrambled 
control siRNA. Changes in FADD expression were detected by Western blotting. 
Compared to untreated cells, endogenous levels of FADD were reduced following 
transfection with 100nM, 150nM or 300nM FADD siRNA (figure 4.1a). As we 
wanted to determine what effect a reduction in FADD would have on poly I:C-
induced IP-10 production, THP1 monocytes were transfected with either 100nM of 
FADD siRNA or100nM scrambled control siRNA and differentiated into 
macrophages, and then stimulated with and without 20μg/ml poly I:C (figure 4.1b). 
However, transfection of THP1 macrophages with both scrambled control siRNA 
and FADD-specific siRNA completely abrogated the capacity of the cells to respond 
to poly I:C (figure 4.1b). To ensure that THP1 macrophages were still responsive to 
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poly I:C, non-transfected cells were also stimulated with poly I:C, which induced a 
3.5 fold increase in IP-10 protein production (figure 4.1c). This indicates that the 
effect observed following siRNA knockdown was most likely due to the transfection 
of the cells with siRNA and as a result we were unable to utilise this technique. 
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Figure 4.1: Transfection of THP-1 macrophages with either scrambled control 
siRNA or FADD-specific siRNA suppressed the ability of the cells to produce 
IP-10 in response to poly I:C. THP-1-derived macrophages were transfected with 
100nM, 150nM and 300nM FADD siRNA. 24 hrs later, FADD expression was 
detected by Western Blotting (a). THP-1 monocytes were transfected with either 
scrambled siRNA control or FADD specific siRNA and derived into macrophages 
over 72 hrs. Cells were then stimulated with 20μg/ml poly I:C for 48 hrs, and IP-10 
production detected by ELISA. (b). Non-transfected THP-1-derived macrophages 
were stimulated with 20μg/ml poly I:C for 48 hrs, and IP-10 production  detected by 
ELISA (c). Results shown are representative of three separate experiments. 
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4.2.2 Absence of FADD augments poly I:C-induced IP-10 transcription and 
inhibits poly I:C-induced IFNβ production.  
As we encountered significant difficulties with the siRNA method, we next 
investigated the role of FADD in poly I:C-induced IP-10 production using murine 
embryonic fibroblasts (MEFs) which lack the Fas adaptor protein FADD (FADD
-/-
 
MEFs). Wild-type and FADD
-/-
 MEFs were stimulated with increasing 
concentrations of poly I:C and expression of IP-10 analysed by qRT-PCR. Induction 
of IP-10 by poly I:C was significantly increased in FADD
-/-
 MEFs as compared to 
wild-type MEFs at all doses examined (p <0.05) (figure 4.2a). As previous studies 
have demonstrated an essential role for FADD in the type-1 interferon production via 
RIG-I (166), we also investigated the ability of  poly I:C to induce IFNβ production 
in these cells (figure 4.2b). In contrast to IP-10 production, poly I:C-induced IFNβ 
production was decreased in FADD
-/-
 MEFs when compared to wild-type MEFs 
(figure 4.2b). While these results were not statistically significant, they are consistent 
with the previously published findings that FADD is required for poly I:C-induced 
IFNβ production (165, 166). We also investigated the role of FADD on poly I:C-
induced CCL20 production. Both wild-type and FADD
-/-
 MEFs showed similar 
levels of CCL-20 expression following poly I:C stimulation, suggesting that FADD 
may not be required for poly I:C-induced CCL-20 production. 
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Figure 4.2: Absence of FADD augments poly I:C-induced IP-10 transcription 
and inhibits poly I:C-induced IFNβ production. Wild type and FADD -/- MEFs 
were stimulated with increasing concentrations of poly I:C (25, 50 and 100ng/ml) for 
8 hrs, with mRNA expression measured using qRT-PCR and normalised to GAPDH. 
Changes in IP-10 (a), IFNβ (b) and CCL-20 (c) mRNA were expressed relative to 
untreated cells. Values shown as Mean ± SEM, (n=3). * p<0.05 
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4.2.3 IP-10 production is reduced following overexpression of FADD in three 
cell lines.    
Given that deletion of FADD resulted in enhanced poly I:C-induced IP-10 
production, we sought to further confirm a role for FADD in this pathway using 
overexpression studies. The murine macrophage cell line RAW264.7 was transfected 
with plasmids encoding an IP-10 luciferase reporter construct and increasing doses 
of FADD (figure 4.3a). Stimulation of these cells with poly I:C induced IP-10 
luciferase activation, with IP-10 luciferase production reduced by FADD in a dose 
dependent manner (figure 4.3a). Based on these results, a concentration of 40ng 
FADD was selected for further luciferase experiments. The ability of 40ng of FADD 
to suppress poly I:C-induced luciferase activation was first confirmed in RAW 264.7 
cells (figure 4.3b). This finding was subsequently confirmed using the human 
astrocytoma cell line U373 (figure 4.3c) and human embryonic kidney cells HEK-
293/TLR3 (figure 4.3d), with poly I:C-induced IP-10 luciferase activation reduced 
upon overexpression of FADD in both cell lines (figure 4.3c, d). 
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Figure 4.3: FADD reduces poly I:C-induced IP-10 production. Cells were 
transfected with IP-10 luciferase and TK-renilla reporter plasmid. RAW264.7 cells 
were also transfected with increasing concentrations of FADD plasmid (4, 20, 50 and 
100ng) and stimulated 24 hrs after transfection with 25μg/ml poly I:C for 6hrs (a). 
RAW 264.7 cells were transfected with 40ng IP-10 luciferase construct and/or 
stimulated 24 hrs after transfection with 25μg/ml poly I:C (b). U373 and HEK-
293/TLR-3 cells were also transfected with 40ng FADD and/or stimulated 24 hrs 
after transfection with 25ng/ml poly I:C and 20ng/ml respectively for 6 hrs (c, d). IP-
10 luciferase activity was measured and expressed as fold-change over TK-renilla 
activity. Data shown are representative of three independent experiments with values 
shown as Mean ± SEM. *** p<0.001 
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4.2.4 Overexpression of cells with FADD-DD plasmid enhances poly I:C-
induced IP-10 luciferase activation in U373 cells. 
The role of FADD was also confirmed using a plasmid encoding the death-domain 
of FADD (FADD-DD), a known dominant negative of FADD, which binds to 
FADD and inhibits its activity. In contrast to the findings obtained following 
transfection of FADD plasmid (figure 4.3c), transfection of U373 cells with the 
FADD-DD construct augmented poly I:C-induced IP-10 luciferase activation (figure 
4.4), adding further evidence that FADD inhibits poly I:C-induced IP-10 production.  
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Figure 4.4: Poly I:C-induced IP-10 luciferase production is augmented by 
overexpression of the death domain of FADD (FADD-DD). U373-CD14 were 
transfected with the IP-10 luciferase construct and TK-renilla construct with/without 
40ng FADD-DD. Cells were stimulated 24 hrs after transfection with 25μg/ml poly 
I:C for 6 hrs. IP-10 luciferase activity was measured and expressed as fold-change 
over TK-renilla activity. Data shown are representative of three independent 
experiments with values shown as Mean ± SEM. ** p<0.01 
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4.2.5 FADD is required for poly I:C-induced ISRE luciferase activation. 
Our data thus far has demonstrated that poly I:C-induced IP-10 luciferase activity is 
reduced following overexpression of FADD, implying that FADD may inhibit poly 
I:C-induced IP-10 production. Given the findings of previously published studies 
demonstrating that FADD is required for poly I:C-induced type-1 IFN production we 
next investigated the role of FADD in poly I:C-induced interferon-stimulated 
response element (ISRE) luciferase activation. U373 cells were transfected with 
plasmids encoding an ISRE luciferase reporter construct and FADD. Stimulation of 
these cells with poly I:C resulted in a 6 fold increase in ISRE luciferase activation. In 
contrast to the inhibitory effect of FADD overexpression seen on the IP-10 luciferase 
construct (figure 4.3), poly I:C-induced ISRE activation was slightly enhanced by 
FADD (figure 4.5a). This requirement for FADD in poly I:C-induced ISRE 
luciferase production was confirmed using a plasmid encoding the FADD-DD. In 
contrast to transfection of full-length FADD construct, transfection of U373 cells 
with the FADD-DD construct reduced poly I:C-induced ISRE luciferase activation 
(figure 4.5b). Thus, in contrast to the inhibitory effect seen with FADD on poly I:C-
induced IP-10 production, our results demonstrate that FADD is required for poly 
I:C-induced ISRE luciferase activity. This is consistent with our results which 
showed that poly I:C-induced IFNβ production is reduced following Fas activation 
(chapter 3, figure 3.6a), and augmented in FADD
-/-
 MEFs (figure 4.2b).  
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Figure 4.5: FADD is required for poly I:C-induced ISRE luciferase activation. 
U373 cells were transfected with ISRE luciferase and TK-renilla reporter plasmid, 
with 40ng FADD (a) or 40ng FADD-DD (b). After 24 hrs, cells were stimulated 
with 20μg/ml poly I:C. ISRE luciferase activity was measured and expressed as fold-
change over TK-renilla activity. Data shown are representative of three independent 
experiments with values shown as Mean ± SEM. ** p<0.01, *** p<0.001 
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4.2.6 Overexpressing FADD reduces RIG-I-, MDA5-, TLR3- and TRIF-induced 
IP-10 luciferase activity. 
Our data thus far demonstrates that FADD modulates poly I:C-induced cytokine and 
chemokine production, with FADD specifically inhibiting poly I:C-induced IP-10 
production. Whilst FADD has been previously implicated in modulating RIG-I-
induced cytokine production (165, 166), poly I:C is known to be detected by the 
viral receptors RIG-I, MDA5 and TLR3, and the role for FADD in MDA5 and TLR3 
signalling is not fully characterised. Therefore, we first wished to investigate if 
FADD was having a specific effect on the ability of any of these receptors to induce 
IP-10 production. To assess this, cells were initially transfected with plasmids 
encoding an IP-10 luciferase reporter construct, FADD and/or RIG-I (figure 4.6a). 
Transfection of cells with RIG-I plasmid alone induced IP-10 production of 
luciferase activity regulated by full length IP-10 promoter, which was reduced upon 
co-transfection with FADD (figure 4.6a). Cells were also transfected with an IP-10 
luciferase construct, FADD and/or MDA5 (figure 4.6b). Transfection of cells with 
MDA5 also induced IP-10 luciferase activation, with overexpressing FADD 
reducing MDA5-induced IP-10 luciferase activation (figure 4.6b).  
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Figure 4.6: FADD reduces RIG-I and MDA5-induced IP-10 production. HEK-
293T cells were transfected with IP-10 luciferase and TK-renilla reporter plasmid. 
Cells were also transfected with 40ng/ml FADD and 80ng/ml RIG-I (a) or 40ng/ml 
FADD and 80ng MDA5 (b). IP-10 luciferase activity was measured and expressed 
as fold-change over TK-renilla activity. Data shown are representative of three 
independent experiments with values shown as Mean ± SEM. ** p<0.01, *** 
p<0.001 
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As poly I:C is also recognised by TLR3, we next investigated the role of FADD in 
TLR3-induced IP-10 luciferase production. Cells were transfected with plasmids 
encoding an IP-10 luciferase reporter construct, FADD and/or TLR3 (figure 4.7a). 
Transfection of cells with TLR3 plasmid alone induced IP-10 production, which was 
reduced upon co-transfection with FADD (figure 4.7a). TLR3-induced IP-10 
luciferase activation was not inhibited when cells were co-transfected with FADD-
DD plasmid, indeed levels were slightly augmented (figure 4.7b). 
Cells were also transfected with plasmids encoding an IP-10 luciferase reporter 
construct, FADD and/or the TLR3 adaptor protein TRIF (figure 4.7c). Similar to 
results shown with TLR3, transfection of cells with TRIF induced IP-10 luciferase 
activation, which was reduced upon co-transfection with FADD (figure 4.7c). TRIF 
induced IP-10 luciferase activation was enhanced however, following co-transfection 
with FADD-DD (figure 4.7d). Taken together, these results demonstrate that TLR3-
and TRIF-induced IP-10 luciferase activity was reduced by FADD, demonstrating a 
role for FADD in the TLR3/TRIF mediated pathway of IP-10 production.  
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Figure 4.7: FADD reduces TLR-3- and TRIF-induced IP-10 production. HEK-
293T cells were transfected with IP-10 luciferase and TK-renilla reporter plasmid. 
Cells were also transfected with 40ng FADD or 40ng FADD-DD, together with 40ng 
TLR-3 (a, b) or 80ng TRIF (c, d). IP-10 luciferase activity was measured and 
expressed as fold-change over TK-renilla activity. Data shown are representative of 
three independent experiments with values shown as Mean ± SEM. ** p<0.01, *** 
p<0.001, ns – non significant. 
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Taken together, these results suggest that FADD reduces RIG-I-, MDA5-, TLR3- 
and TRIF-mediated IP-10 luciferase activation and also indicates that the inhibitory 
effect of FADD on poly I:C-induced IP-10 production is not specific to any viral 
RNA receptor. 
4.2.7 Overexpression of FADD has no effect on RIP-1- or IKKε-induced IP-10 
luciferase activation.     
As it appeared that FADD was specifically inhibiting poly I:C-mediated IP-10 
production, and not IFNβ and that this modulatory effect was not specific to TLR3, 
RIG-I or MDA5, we hypothesised that FADD may be exerting an inhibitory effect at 
a specific point on the pathways downstream of these receptors. In an attempt to 
identify where FADD may be having this effect, we next transfected cells with 
plasmids encoding RIP-I and IKKε. Both RIP-1 (65, 195) and IKKε (196, 197) are 
downstream of TLR3, RIG-I and MDA5. Transfection with either RIP-1 or IKKε 
alone induced IP-10 luciferase activation, which was slightly enhanced upon co-
expression of FADD (figure 4.8a, c). Overexpression of the FADD-DD however, 
had no effect on either RIP-1 or IKKε IP-10 luciferase activation (figure 4.8b, d). As 
FADD did not inhibit IP-10 luciferase activation driven by signalling components 
downstream of poly I:C receptors or the adapter TRIF, our results suggested that 
FADD may reduce IP-10 luciferase activation at the level of receptors themselves or 
the adapter TRIF.  
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Figure 4.8: FADD does not inhibit RIP-1- and IKKε-induced IP-10 production. 
HEK-293T cells were transfected with IP-10 luciferase and TK-renilla reporter 
plasmid, with 40ng FADD or 40ng FADD-DD, together with 80ng RIP-1 (a, b) or 
80ng IKKε (c, d). IP-10 luciferase activity was measured and expressed as fold-
change over TK-renilla activity. Data shown are representative of three independent 
experiments with values shown as Mean ± SEM. * p<0.05, *** p<0.001 
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4.2.8 Co-immunoprecipitation of VSV-TRIF and FLAG-FADD was 
unsuccessful in detecting an interaction between TRIF and FADD. 
Whilst FADD has never been shown to directly interact with TRIF, previous studies 
have demonstrated an indirect interaction, mediated through a complex containing 
TRIF/FLIP/RIP-1 (130). As our luciferase data indicated an ability of FADD to 
inhibit TRIF-induced IP-10 production, but not any components further downstream, 
we hypothesised that FADD may directly interact with TRIF. To investigate this, 
HEK-293T cells were initially transfected with different concentrations of a VSV-
tagged TRIF construct (figure 4.9a) and a FLAG tagged FADD construct (figure 
4.9b) and Western blotting performed with anti-VSV antibody and anti-Flag 
antibody respectively. Transfection of the FLAG-FADD construct was initially 
optimised.  Transfection of cells with both 2μg and 4μg Flag-FADD resulted in 
expression of the protein (figure 4.9a). We subsequently attempted to optimise 
overexpression of the VSV-TRIF construct. Initial optimisation experiments were 
performed using 1, 2, 4 and 10μg of VSV-tagged TRIF. It was noted however, that 
following transfection of the higher doses of VSV-tagged TRIF, extensive cell death 
was observed. Therefore, we optimised the overexpression of TRIF at lower 
concentrations. While we did not observe a band in cells transfected with 1μg VSV-
TRIF, a faint band was observed following Western blotting with anti-VSV in cells 
transfected with 2μg VSV-TRIF (figure 4.9b).  
HEK-293T cells were next transfected with the optimal concentration of VSV-TRIF 
(2μg) with or without FLAG-FADD and co-immunoprecipitation was performed 
(figure 4.9c). Immunoprecipitation for both VSV and FLAG were performed. 
Following immunoprecipitation with the VSV antibody and immunoblotting for 
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FLAG, a band was detected in all samples at approximately 23-26kDa. This band, 
which is most likely Light chain of the immunoprecipitating antibody (anti-VSV), 
ran at the same size at FADD (26kDA) and therefore may mask any potential 
interactions that we may have observed (figure 4.9c). We also performed the same 
experiment in the reverse direction, immunoprecipitating with anti-Flag and 
immunoblotting with anti-VSV (figure 4.9d). In this experiment the same band at 
26kDA can be observed as was seen in figure 4.9c. Moreover no band corresponding 
to the correct size for VSV-tagged TRIF (75kDa) was observed, perhaps reflecting 
the very low level of expression of VSV-TRIF as seen in figure 4.9b. Similar results 
were obtained three times, and therefore we were unable to identify an interaction 
between FADD and TRIF.     
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Figure 4.9: Co-immunoprecipitation of VSV-TRIF and FLAG-FADD was 
unsuccessful in detecting an interaction between TRIF and FADD in HEK-293T 
cells. HEK-293T cells were transfected with either FLAG-FADD (a) or VSV-TRIF 
(b) and immuno-blotting performed for anti-FLAG or anti-VSV respectively. 
Optimal concentrations of both FLAG-FADD and VSV-TRIF were selected, with 
cells either untransfected or transfected with 2μg/ml VSV-TRIF with and without 
4μg/ml FLAG-FADD (c, d). Immuno-precipitation was performed. Samples which 
were immunoprecipitated with anti-VSV were immunoblotted for FLAG (c). 
Similarly, samples immunoprecipitated with anti-FLAG were immunoblotted for 
VSV (d).  
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4.2.9 Co-stimulation with poly I:C and CH11 reduces poly I:C-induced 
phosphorylation of JNK and p38 MAP Kinases (MAPKs).  
Thus far our data demonstrates that Fas activation enhances viral-induced IP-10 
production. We have also shown that over-expressing FADD inhibits TLR3-, 
MDA5- and RIG-I-induced IP-10 production in a non-receptor specific manner, 
thereby directly implicating FADD in this process. However, we had not yet defined 
a precise molecular mechanism by which FADD is able to modify poly I:C-induced 
IP-10 production. Furthermore, it was increasingly difficult to comprehend how 
FADD could specifically inhibit levels of IP-10, whilst either augmenting or not 
affecting other cytokines, such as IFNβ. To address these issues we decided to 
examine the ability of the Fas/FADD pathway to modify signalling components 
common to all three viral receptors. As these receptors can activate both NFκB and 
the MAP Kinase (MAPK) signalling pathways, we initially investigated whether 
poly I:C-induced activation of these signalling intermediates was altered in FADD
-/-
 
MEFs compared to wild-type MEFs. The results of these experiments however were 
inconclusive. In spite of loading the maximum amount of protein (i.e. lysing samples 
directly in sample buffer) and increasing antibody concentration, only faint bands 
were observed upon probing. Similarly, consistent banding patterns were not 
achieved over three independent experiments. This may be due to variations in 
protein loading. Therefore the same experimental model as utilised in the previous 
chapter was employed. THP1 cells were stimulated with CH11, followed by poly I:C 
stimulation, and phosphorylation of signalling intermediates downstream of poly I:C 
was measured. While poly I:C-induced phosphorylation of IκBα and p42/p44 MAPK 
was unaffected by CH11, Fas activation by CH11 followed by poly I:C stimulation 
resulted in markedly reduced phosphorylation of the MAP kinase p38 at 15, 30 and 
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60 minutes of stimulation, relative to poly I:C alone (figure 4.10). Similarly, 
phosphorylation of JNK was also reduced at 30 and 60 minutes.  
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Figure 4.10: Ligation of Fas suppresses poly I:C-induced phosphorylation of 
JNK and p38 MAPK. THP-1 macrophages were treated with CH11 1 hr prior to 
poly I:C stimulation for 15, 30 and 60 mins. pIκBα, phospho-p42/44 MAPK, 
phospho-p38 MAPK, phospho-JNK and βactin were detected by Western blotting. 
Data shown are representative of three independent experiments.  
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4.2.10 The AP-1 transcription factor negatively regulates IP-10 production.  
Phosphorylation of JNK and p38 MAPK are known to result in activation of the 
transcription factor AP-1. As the IP-10 promoter contains an AP-1 binding site, we 
next examined the IP-10 promoter using IP-10 promoter luciferase constructs 
mutated at the ISRE binding site, two separate NFκB binding sites (κB1, κB2) and 
the AP-1 binding site (figure 4.11a). Interestingly, cells transfected with the IP-10 
promoter mutated at the AP-1 binding site showed augmented IP-10 luciferase 
activation in response to poly I:C (figure 4.11b). This augmentation parallels the 
increased IP-10 expression seen upon co-stimulation with CH11 and poly I:C 
(chapter 3, figure 3.7). In contrast, poly I:C-induced IP-10 activation was reduced 
following mutation of two separate NFκB binding sites (figure 4.11c, d) and also of 
the ISRE binding site (figure 4.11e). These results indicate that the AP-1 
transcription factor represses poly I:C-induced IP-10 production.  
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Figure 4.11: AP-1 negatively regulates the IP-10 promoter in response to poly 
I:C. HEK-293/TLR3 cells were transfected with full length IP-10 luciferase 
plasmids or IP-10 luciferase plasmids containing point deletions in the binding sites 
for proximal AP-1, NF-κB (κB1, κB2), or ISRE. A schematic of these putative 
binding sites is illustrated (a). 24 hrs post transfection, cells were stimulated with 
20μg/ml poly I:C for 6 hrs with IP-10 luciferase activity expressed as fold-change 
over TK-renilla activity (b, c, d, e). Data shown are representative of three 
independent experiments with values shown as Mean ± SEM. ** p<0.01, *** 
p<0.001 
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4.2.11 Overexpression of FADD activates AP-1 luciferase activation. 
Thus far we have shown that Fas ligation modifies poly I:C-induced phosphorylation 
of transcription factors upstream of AP-1. We have also demonstrated that AP-1 is 
inhibitory to poly I:C-induced IP-10 production. In order to demonstrate that Fas, 
through its adapter FADD, can affect AP-1 activation and thereby potentially explain 
the ability of Fas to upregulate poly I:C-induced IP-10, we next investigated whether 
transfection of cells with FADD altered activation of an AP-1 luciferase construct. 
Activation of AP-1 by FADD was low but was consistently enhanced in a dose- 
dependent manner upon transfection with FADD, with TNFα inducing a moderate 
induction in AP-1 activity (figure 4.12). As we have demonstrated that AP-1 
negatively regulates IP-10 production, and that FADD enhances AP-1 activity, we 
have identified a potential mechanism by which Fas activation may modulate viral-
induced IP-10 production. We hypothesise that Fas activation results in recruitment 
of the FADD adapter protein to the DISC complex (114), thereby limiting the levels 
of FADD in the cytoplasm. This would alleviate the repression of AP-1 by reducing 
phosphorylation of both JNK and p38 MAPK. This potential mechanism of 
upregulation of poly I:C-induced IP-10 by Fas is illustrated in figure 4.13.  
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Figure 4.12: Overexpression of FADD induces AP-1 luciferase activation. 
HEK293/TLR3 cells were transfected with an AP-1 luciferase reporter construct. 
Cells were also transfected with the indicated doses of FADD. 24 hrs after 
transfection cells were stimulated with 20μg/ml poly I:C or 20ng/ml TNFα further 6 
hrs. AP-1 luciferase activity was measured and expressed as fold-change over TK-
renilla activity. Data shown are representative of three independent experiments with 
values shown as Mean ± SEM. * p<0.05 
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4.3 Discussion 
The findings in this chapter demonstrate a role for FADD in regulating viral-induced 
IP-10 production. Over-expression studies revealed that FADD inhibits TLR3-, RIG-
I- and MDA-5- induced IP-10 production. Investigation of signalling intermediates 
demonstrated that Fas activation reduces poly I:C-induced phosphorylation of both 
JNK and p38 MAPK, with mutation of the AP-1 transcription factor binding site on 
the IP-10 promoter resulting in enhanced poly I:C-induced IP-10. The Fas adapter 
protein FADD enhanced the luciferase activity of the AP-1 transcription factor. 
Therefore, we hypothesise that upon Fas activation, FADD is recruitment to the Fas 
receptor thus reducing the amount of FADD present in the cytoplasm. This in turn 
reduces activation of the AP-1 transcription factor thus alleviating AP-1 mediated 
repression of the IP-10 promoter and enhancing IP-10 production (figure 4.13). 
In chapter 3 we observed that Fas activation reduced poly I:C-induced IFNβ 
production. In this chapter, we have shown that an absence of FADD (FADD
-/-
MEFs) reduced poly I:C-induced IFNβ production, indicating that FADD may be a 
critical signalling component in this pathway. Previous studies investigating the role 
of FADD in poly I:C signalling have also shown that FADD is a critical component 
of the RIG-I signalling pathway, whereby production of type 1 IFNs in response to 
intracellular dsRNA was defective in FADD
-/-
 MEFs (165). This study demonstrated 
that FADD
-/-
 MEFs had increased replication of vesicular stomatitis virus (VSV) 
with respect to wild-type MEFs, and while transfection of the dsRNA mimetic poly 
I:C still induced a low level of IFNβ in FADD-/- MEFs, more robust IFNβ production 
was observed in FADD
+/-
 MEFs (165). In a separate study, this group also 
demonstrated that FADD was essential for RIG-I-, MDA5- and MAVS/IPS-1-
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induced IFNβ production, with overexpression of these receptors inducing enhanced 
IFNβ luciferase activation following poly I:C stimulation in FADD+/- MEFs when 
compared to FADD
-/-
 MEFs  (166). They also demonstrated that FADD was also 
required for poly I:C-induced IRF7 expression with poly I:C inducing expression of 
IRF7 in FADD
+/-
 MEFs, with no induction in expression observed in FADD
-/-
 MEFs 
(166). Therefore, our data provides further evidence that FADD is required for poly 
I:C-induced IFNβ production.   
In contrast to the data shown here concerning the essential role of FADD in IFNβ 
production, we have identified that overexpression of FADD inhibits IP-10 
production and that a more robust induction in poly I:C-induced IP-10 production is 
observed in FADD
-/-
 MEFs when compared to wild-type MEFs. Interestingly, this is 
in contrast to a study published by Zhande et al (159). Using a similar experimental 
design to our study, they exposed both wild-type and FADD
-/- 
MEFs to poly I:C and 
analysed IP-10 production (159). IP-10 production was measured by ELISA, with 
wild-type MEFs showing enhanced IP-10 production when compared to FADD
-/-
 
MEFs (159). It seems possible that these differences could be explained by a 
difference in the generation of the FADD knockout MEFs. The cell line that we used 
was obtained from Dr. Tak W. Mak in the University of Toronto, whereas that used 
by Zhande et al. was obtained from Amgen, Inc., therefore differences in animal 
units, and the genetic background of the mice may account for the contrasting results 
observed. Also, in our study we have confirmed the specific modulation of poly I:C-
induced IP-10 production by Fas stimulation using FADD
-/- 
MEFs and using 
overexpression experiments involving both FADD and the FADD-DD. Moreover, 
these experiments were performed in multiple cell lines and multiple species. Our 
data is therefore strengthened by the variety of techniques and cell lines used as 
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compared to Zhande et al. who only examined IP-10 production in FADD
-/- 
MEFs. It 
is worth noting that the other published studies investigating the role of FADD in 
poly I:C responses did not examine levels of IP-10. Furthermore, an inhibitory role 
for FADD in cytokine production was recently shown in another study. This study 
identified a novel interaction between FADD and TRIM21, and showed that 
overexpression of FADD and TRIM21 was able to repress both IRF7 
phosphorylation and transcriptional activity. Loss of FADD and TRIM21 led to 
higher levels of IFNα induction in response to Sendai virus (198). These authors 
concluded that this complex constitutes a negative feedback loop of late IFNα 
pathway during viral infection (198), indicating that FADD negatively regulates 
IFNα (198). Our data concerning IP-10 is consistent with these findings for an 
inhibitory role for FADD as we have shown that, with respect to dsRNA-induced IP-
10 production, FADD is able to repress IP-10 production. 
The ability of FADD to inhibit poly I:C-induced IP-10 production does not appear to 
be receptor specific, as over-expression of FADD inhibited RIG-I-, MDA5-, TLR3 
and TRIF-induced IP-10 luciferase activation. Interestingly, FADD did not either 
inhibit RIP-1- or IKKε-induced IP-10 production. Upon dsRNA recognition, TLR3 
recruits the adapter protein TRIF for activation of downstream signalling 
components, while both RIG-I and MDA5 recruit the adapter protein IPS-1 (70). 
Both RIP-1 and IKKε are utilised by both RIG-I and TRIF, activating NFκB and IRF 
3/7 respectively (70). Both NFκB and the IRFs regulate IP-10 production (199-201). 
Given that FADD and RIP-1 have previously been shown to be in a complex (130), 
it may have been expected that FADD would also inhibit RIP-1-induced IP-10 
production. Instead a slight augmentation of RIP-1-induced IP-10 was observed 
upon co-transfection of cells with FADD and RIP-1. RIP-1 is known to be a key 
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component of the RIG-I signalling pathway. In this pathway RIP-1 and FADD have 
been shown to interact in a complex with IPS-1, and this interaction is essential for 
RIG-I-induced production (65). Thus, the failure of FADD to inhibit RIP-1-induced 
IP-10 is possibly due to the involvement of RIP-1 in the RIG-I signalling and may 
indicate additional complexities of FADD in RIG-I-induced IP-10 production that 
remain to be elucidated.  
As mentioned above FADD has been shown to be in a complex with RIP-1 and this 
complex also includes the adapter TRIF as well as caspase-8 (130). As we had 
observed that overexpression of FADD could inhibit TRIF-induced IP-10 and were 
unable to show inhibition of other downstream signalling proteins, it seemed 
possible that FADD could be interacting with TRIF directly. TRIF is a 76kDa 
protein containing several potential binding domains for protein-protein interactions. 
It contains a conserved TIR domain through which it interacts with TLR3 (52). 
Three TRAF-binding motifs present in the amino terminal region of TRIF are 
necessary for association with TRAF6. Destruction of these motifs reduces the 
activation of NFκB (202). It also contains a RIP homotypic interaction motif 
(RHIM) through which it recruits RIP-1 and RIP-3 (195), essential for activation of 
apoptosis (172). Similarly the protein structure of FADD is well characterised. It is a 
26kDa protein containing two conserved domains: the death domain (DD), and the 
death effector domain (DED) (194), required for downstream signalling following 
receptor activation. Whilst none of these domains in TRIF or FADD would be 
classically considered to be protein-protein interacting domains, we nonetheless 
performed co-immunoprecipitation experiments to try to determine whether these 
proteins interacted. Unfortunately, the results of the TRIF-FADD co-
immunoprecipitation experiment were inconclusive. Whilst we were able to detect 
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overexpression of both TRIF and FADD during optimisation of the experiments, 
following immunoprecipitation, it is possible that the Light chain, apparent at 23-
26kDa, is masking any possible interaction between FADD and TRIF. Also, as 
overexpression of TRIF resulted in the detection of a faint band, this suggests that 
the quantity of TRIF present may not have been sufficient to detect any interaction, 
however, a higher concentration could not be used as optimisation experiments using 
higher concentrations of TRIF resulted in cell death. Thus it remains to be fully 
clarified whether FADD and TRIF interact directly. 
As we had observed that FADD over expression inhibited at the level of the 
receptors for poly I:C and also at the level of the adapter TRIF but were unable to 
pinpoint where on the pathway this inhibitory effect may be occurring we next 
examined the ability of the Fas/FADD pathway to modify the phosphorylation status 
of downstream signalling components common to all poly I:C receptors. We 
demonstrated that poly I:C-induced phosphorylation of p44/42, IκBα, JNK and p38 
MAPK, with activation of Fas reducing the phosphorylation of JNK and p38 MAPK. 
IκBα is a regulatory protein which sequesters NFκB in the cytoplasm, therefore 
limiting the transcriptional activity of NFκB. However, upon activation, IκBα 
becomes phosphorylated, releasing its hold on NFκB, allowing NFκB to migrate to 
the nucleus, inducing its transcriptional activity. Given our earlier findings that 
overexpression of FADD did not alter RIP-1-induced IP-10 luciferase activity, and 
the important role of RIP-1 in activating NFκB, it was not surprising that Fas 
activation did not alter the phosphorylation status of IκBα. JNK and p38 MAPK are 
known to be involved in the activation of the AP-1 transcription factor. AP-1 is 
composed of the sub-families c-Jun and c-Fos, as well as the Maf 
(musculoaponeurotic fibrosarcoma) and ATF (activating transcription factor) 
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subfamilies, all of which are dimeric basic region-leucine zipper (bZIP) proteins 
(203). c-Fos and c-Jun are the main AP-1 proteins, with c-Fos proteins requiring c-
Jun proteins to form stable heterodimers as they are not capable of forming 
homodimers (203). We have demonstrated that mutation of the AP-1 binding site 
augmented IP-10 transcription, indicating that AP-1 inhibits the IP-10 promoter. 
This finding may explain our data concerning opposing roles of FADD on the same 
poly I:C pathway. It would seem that it is not that FADD is exerting a direct 
inhibitory effect on IP-10, but rather that it is somewhat specifically modulating the 
AP-1 transcription factor, with the AP-1 transcription factor in turn repressing the 
IP-10 promoter. Thus, the ability of CH11 to reduce poly I:C-induced 
phosphorylation of JNK and p38 MAPK may result in a reduction in the level of AP-
1 binding to the IP-10 promoter, thus alleviating the AP-1-mediated repression of IP-
10. Consistent with this, a similar inhibitory role for AP-1 on the IP-10 promoter was 
recently shown in hepatocytes following Hepatitis C (HCV) infection (204). In this 
study, poly I:C-induced IP-10 production was reduced upon point mutation in the 
κB1, κB2 and ISRE binding sites of the IP-10 promoter, with a point mutation in the 
AP-1 binding site enhancing IP-10 production. Although this study did not 
investigate the role of Fas during HCV infection, hepatocytes are known to express 
Fas (205) and thus the system that we have identified here suggests that activation of 
the Fas signalling pathway in hepatocytes during HCV infection may play an 
important role in the induction of IP-10 in these cells.  
As we had shown that Fas can reduce phosphorylation of poly I:C-induced p38 and 
JNK MAPK and that AP-1 is inhibitory to poly I:C-induced IP-10, we wished to link 
these findings by identifying that the Fas/FADD system could directly modify AP-1. 
Here we have shown that overexpression of FADD activates an AP-1 luciferase 
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reporter construct. Thus, our working hypothesis is that activation of Fas recruits 
FADD to Fas, limiting the levels of FADD available in the cytoplasm. This would 
reduce the inhibitory effect of FADD on p38 and JNK, reducing AP-1 activation and 
alleviating AP-1 mediated repression of IP-10. While our data supports this working 
hypothesis further work is required to make a definitive conclusion. In order to 
investigate this hypothesis fully, electrophoretic mobility shift assay (EMSA) could 
be performed on THP1 macrophages treated with poly I:C with or without CH11 
stimulation, with interaction between AP-1 and its binding site on the IP-10 
promoter examined. Based on our data to date, we would expect to find less AP-1 
bound to IP-10 when cells were stimulated with poly I:C and CH11. Chromatin 
immunoprecipitation assay (ChIP) could also be performed. For ChIP analysis, a 
specific antibody against AP-1 could be used to immunoprecipitate the AP-1/IP-10 
complex, with IP-10 expression measured by qRT-PCR. Based on our findings, we 
would expect to see reduced expression of IP-10 on qRT-PCR analysis in cells 
stimulated with both poly I:C and CH11, compared to poly I:C alone. Also whilst we 
and others have shown that FADD is recruited to Fas upon stimulation with CH11 
(114, 206), we have not shown that this substantially decreases levels of FADD in 
the cytoplasm of the cell such that the ability of signalling pathways that utilise 
FADD would be affected. Although experiments such as these were not performed 
due to time constraints, they would have strengthened the working hypothesis of the 
potential mechanism outlined here for augmented poly I:C-induced IP-10 production 
by Fas activation (figure 4.13). 
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Figure 4.13: Schematic of mechanism whereby Fas activation may enhance poly 
I:C-induced IP-10. In the absence of Fas engagement, poly I:C, acting through both 
TLR3 and RIG-I, cause the  phosphorylation of JNK and p38 MAPK in a FADD 
dependant manner. This results in AP-1 activation and translocation of AP-1 to the 
nucleus, where it acts to repress IP-10 production. Dashed lines indicate that the 
precise position of FADD in this pathway is unknown (a). Upon Fas activation, 
FADD is recruited to Fas, reducing poly I:C-induced JNK and p38 MAPK 
activation. This reduces the levels of AP-1, thereby alleviating AP-1-mediated 
repression of the IP-10 promoter, resulting in enhanced IP-10 production (b). 
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In conclusion, we demonstrate here a role for Fas in modulating poly I:C-induced 
cytokine production. These studies show that ligation of Fas specifically enhances 
IP-10 through modulation of p38 and JNK MAP kinases and the AP-1 transcription 
factor. It is not clear why AP-1 negatively regulates IP-10 and not the other 
cytokines examined here. This study points to a level of complexity present in the 
IP-10 promoter whereby levels of IP-10 are tightly regulated in the anti-viral 
immune response. It may be that there is a requirement for a second activating signal 
such as Fas ligation, ensuring that the promoter is optimally induced during active 
infection. 
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Appendix A 
 
Accession Description Score Coverage # Proteins # Unique Peptides # Peptides # PSMs # AAs MW [kDa] calc. pI 
P13796 Plastin-2 OS=Homo sapiens GN=LCP1 PE=1 SV=6 - 
[PLSL_HUMAN] 
1689.75 51.83 3 26 26 50 627 70.2 5.43 
B4DNE0 cDNA FLJ52573, highly similar to Elongation factor 1-
alpha 1 OS=Homo sapiens PE=2 SV=1 - 
[B4DNE0_HUMAN] 
1470.06 14.94 14 4 4 44 395 42.6 9.01 
P02545-2 Isoform C of Prelamin-A/C n=2 Tax=Homo sapiens 
RepID=P02545-2 
837.86 33.57 4 19 19 25 572 65.1 6.84 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
584.47 31.46 1 11 14 16 639 65.4 8.00 
B4DNW7 Adenylyl cyclase-associated protein OS=Homo 
sapiens PE=2 SV=1 - [B4DNW7_HUMAN] 
486.64 23.09 5 9 9 14 433 47.4 8.22 
P14317 Hematopoietic lineage cell-specific protein 
OS=Homo sapiens GN=HCLS1 PE=1 SV=3 - 
[HCLS1_HUMAN] 
442.58 17.49 1 7 7 13 486 54.0 4.81 
B3KVX6 cDNA FLJ41699 fis, clone HCHON2004776, highly 
similar to Homo sapiens cytoskeleton-associated 
protein 4 (CKAP4), mRNA OS=Homo sapiens PE=2 
SV=1 - [B3KVX6_HUMAN] 
384.95 21.31 4 8 8 10 521 58.1 5.25 
P12314 High affinity immunoglobulin gamma Fc receptor I 
OS=Homo sapiens GN=FCGR1A PE=1 SV=2 - 
[FCGR1_HUMAN] 
373.79 13.37 1 6 6 13 374 42.6 7.97 
P08107-2 Isoform 2 of Heat shock 70 kDa protein 1A/1B n=1 
Tax=Homo sapiens RepID=P08107-2 
359.84 16.04 4 6 8 9 586 63.9 5.71 
Q6ZNL4 FLJ00279 protein (Fragment) OS=Homo sapiens 
GN=FLJ00279 PE=2 SV=1 - [Q6ZNL4_HUMAN] 
275.01 15.63 3 7 7 7 563 65.7 8.85 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens 
GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 
266.60 14.07 1 6 8 8 590 62.3 7.74 
Q5DT20 Hornerin OS=Homo sapiens GN=HRNR PE=2 SV=1 - 
[Q5DT20_HUMAN] 
265.86 10.95 2 7 7 8 2850 282.2 10.02 
E9PKE3 Heat shock cognate 71 kDa protein OS=Homo 
sapiens GN=HSPA8 PE=2 SV=1 - [E9PKE3_HUMAN] 
263.26 12.92 3 5 7 8 627 68.8 5.52 
F5H0T1 Stress-induced-phosphoprotein 1 OS=Homo sapiens 
GN=STIP1 PE=2 SV=1 - [F5H0T1_HUMAN] 
225.30 14.45 5 6 6 7 519 59.7 6.80 
B4DEK4 Sorting nexin-2 OS=Homo sapiens GN=SNX2 PE=2 
SV=1 - [B4DEK4_HUMAN] 
221.82 17.66 6 6 6 6 402 46.1 7.24 
Table A.1: FADD-protein interactions isolated from Mass spectrometry analysis for sample 1, untreated THP-1 macrophages.  
B4DNK4 Pyruvate kinase OS=Homo sapiens PE=2 SV=1 - 
[B4DNK4_HUMAN] 
216.06 15.54 2 5 5 6 457 49.9 7.83 
P20700 Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 SV=2 - 
[LMNB1_HUMAN] 
207.87 15.19 1 6 6 6 586 66.4 5.16 
Q8IUK7 ALB protein OS=Homo sapiens PE=2 SV=1 - 
[Q8IUK7_HUMAN] 
207.83 6.06 13 3 3 6 396 45.1 6.10 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens 
GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 
184.53 14.41 1 4 5 5 472 51.5 5.16 
Q59GL1 Synaptotagmin binding, cytoplasmic RNA interacting 
protein variant (Fragment) OS=Homo sapiens PE=2 
SV=1 - [Q59GL1_HUMAN] 
165.64 10.11 1 5 5 5 534 59.6 8.73 
B4DLW8 Probable ATP-dependent RNA helicase DDX5 
OS=Homo sapiens GN=DDX5 PE=2 SV=1 - 
[B4DLW8_HUMAN] 
147.76 11.03 6 5 5 5 535 60.5 9.07 
P21589-2 Isoform 2 of 5'-nucleotidase n=1 Tax=Homo sapiens 
RepID=P21589-2 
143.75 7.82 5 3 3 3 524 57.9 6.98 
Q03252 Lamin-B2 OS=Homo sapiens GN=LMNB2 PE=1 SV=3 - 
[LMNB2_HUMAN] 
138.11 5.83 2 3 3 3 600 67.6 5.35 
Q9Y3Z3-4 Isoform 4 of Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 n=1 Tax=Homo 
sapiens RepID=Q9Y3Z3-4 
133.21 8.80 3 5 5 5 591 68.1 6.90 
Q8TD55 Pleckstrin homology domain-containing family O 
member 2 OS=Homo sapiens GN=PLEKHO2 PE=2 
SV=1 - [PKHO2_HUMAN] 
107.35 7.14 1 3 3 3 490 53.3 5.43 
Q16555 Dihydropyrimidinase-related protein 2 OS=Homo 
sapiens GN=DPYSL2 PE=1 SV=1 - [DPYL2_HUMAN] 
103.56 6.82 3 3 3 3 572 62.3 6.38 
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial 
OS=Homo sapiens GN=CPT2 PE=1 SV=2 - 
[CPT2_HUMAN] 
92.94 3.34 1 2 2 2 658 73.7 8.18 
B7Z2F4 T-complex protein 1 subunit delta OS=Homo sapiens 
GN=CCT4 PE=2 SV=1 - [B7Z2F4_HUMAN] 
86.89 6.94 5 2 2 2 389 42.3 7.61 
F5GZM7 Tyrosine-protein phosphatase non-receptor type 6 
OS=Homo sapiens GN=PTPN6 PE=2 SV=1 - 
[F5GZM7_HUMAN] 
84.53 24.77 12 2 2 2 109 12.4 6.93 
Q8WWJ8 Integrin beta OS=Homo sapiens PE=2 SV=1 - 
[Q8WWJ8_HUMAN] 
83.22 5.82 7 2 2 2 378 41.8 6.61 
H0YMM1 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 
PE=2 SV=1 - [H0YMM1_HUMAN] 
79.67 16.11 7 2 2 2 149 16.4 5.91 
B4DDC8 cDNA FLJ57252, highly similar to Protein 
phosphatase 2C isoform gamma (EC 3.1.3.16) 
OS=Homo sapiens PE=2 SV=1 - [B4DDC8_HUMAN] 
79.64 4.47 4 2 2 2 515 56.1 4.34 
Q70T18 BBF2H7/FUS protein (Fragment) OS=Homo sapiens 
PE=2 SV=1 - [Q70T18_HUMAN] 
76.12 14.65 13 2 2 2 157 16.1 9.00 
Q9H3P7 Golgi resident protein GCP60 OS=Homo sapiens 
GN=ACBD3 PE=1 SV=4 - [GCP60_HUMAN] 
74.24 7.58 1 2 2 2 528 60.6 5.06 
Q5T0H9 Gelsolin OS=Homo sapiens GN=GSN PE=2 SV=1 - 
[Q5T0H9_HUMAN] 
74.11 6.19 10 2 2 2 485 52.3 5.34 
B3KTA3 Fascin OS=Homo sapiens PE=2 SV=1 - 
[B3KTA3_HUMAN] 
70.71 4.66 4 2 2 2 472 52.2 7.65 
B3KRK8 cDNA FLJ34494 fis, clone HLUNG2005030, highly 
similar to VIMENTIN OS=Homo sapiens PE=2 SV=1 - 
[B3KRK8_HUMAN] 
63.11 5.90 4 2 2 2 407 46.9 5.00 
Q6PK50 HSP90AB1 protein (Fragment) OS=Homo sapiens 
GN=HSP90AB1 PE=2 SV=1 - [Q6PK50_HUMAN] 
62.97 13.11 3 2 2 2 351 40.3 4.97 
Q9H834 cDNA FLJ13966 fis, clone Y79AA1001394, weakly 
similar to CELL DIVISION PROTEIN FTSH HOMOLOG 
(EC 3.4.24.-) OS=Homo sapiens PE=2 SV=1 - 
[Q9H834_HUMAN] 
55.36 3.33 7 2 2 2 480 53.5 9.45 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs MW [kDa] calc. pI 
Q1KLZ0 HCG15971, isoform CRA_a OS=Homo sapiens GN=PS1TP5BP1 PE=2 SV=1 
- [Q1KLZ0_HUMAN] 
5898.81 67.73 4 1 23 184 375 41.7 5.48 
P63261 Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - 
[ACTG_HUMAN] 
5847.44 68.00 1 2 24 183 375 41.8 5.48 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 
- [K2C6B_HUMAN] 
1230.07 15.96 1 1 8 37 564 60.0 8.00 
Q6KB66-2 Isoform 2 of Keratin, type II cytoskeletal 80 n=1 Tax=Homo sapiens 
RepID=Q6KB66-2 
1162.88 7.82 3 2 3 29 422 47.2 5.30 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - 
[K2C5_HUMAN] 
924.93 28.14 1 10 15 28 590 62.3 7.74 
Q5DT20 Hornerin OS=Homo sapiens GN=HRNR PE=2 SV=1 - [Q5DT20_HUMAN] 671.14 17.40 2 13 13 22 2850 282.2 10.02 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 
662.59 36.86 1 7 13 19 472 51.5 5.16 
Q5HYL6 Putative uncharacterized protein DKFZp686E1899 OS=Homo sapiens 
GN=DKFZp686E1899 PE=2 SV=1 - [Q5HYL6_HUMAN] 
525.29 30.40 2 9 9 13 352 39.5 5.19 
Q6ZNL4 FLJ00279 protein (Fragment) OS=Homo sapiens GN=FLJ00279 PE=2 SV=1 
- [Q6ZNL4_HUMAN] 
486.63 19.89 3 8 8 12 563 65.7 8.85 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 467.73 6.20 1 14 14 15 2871 331.6 6.81 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - 
[K1C16_HUMAN] 
396.32 20.93 1 3 9 12 473 51.2 5.05 
P04075 Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 
SV=2 - [ALDOA_HUMAN] 
365.10 35.71 1 9 9 11 364 39.4 8.09 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 356.17 7.91 1 6 6 8 1049 113.7 5.03 
F2XI28 MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 
- [F2XI28_HUMAN] 
313.14 32.23 1 3 7 8 273 31.6 6.47 
P14923 Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 - 
[PLAK_HUMAN] 
287.05 9.80 1 6 6 8 745 81.7 6.14 
P61160 Actin-related protein 2 OS=Homo sapiens GN=ACTR2 PE=1 SV=1 - 
[ARP2_HUMAN] 
228.43 14.97 1 5 5 7 394 44.7 6.74 
B4DU58 cDNA FLJ51488, highly similar to Macrophage capping protein 
OS=Homo sapiens PE=2 SV=1 - [B4DU58_HUMAN] 
225.87 25.38 3 7 7 7 327 36.2 6.25 
Q6YHK3-2 Isoform 2 of CD109 antigen n=1 Tax=Homo sapiens RepID=Q6YHK3-2 206.14 3.51 3 4 4 5 1368 152.6 5.64 
Q08188 Protein-glutamine gamma-glutamyltransferase E OS=Homo sapiens 
GN=TGM3 PE=1 SV=4 - [TGM3_HUMAN] 
64.15 3.90 1 2 2 2 693 76.6 5.86 
Table A.2: FADD-protein interactions isolated from Mass spectrometry analysis for sample 2, THP-1 macrophages treated with 
200ng/ml CH11.  
H0YKS4 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=3 SV=1 - 
[H0YKS4_HUMAN] 
149.14 31.82 5 5 5 5 176 19.5 5.96 
H2AM05 MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 
- [H2AM05_HUMAN] 
146.79 16.48 1 1 5 6 273 31.4 5.67 
P24752 Acetyl-CoA acetyltransferase, mitochondrial OS=Homo sapiens 
GN=ACAT1 PE=1 SV=1 - [THIL_HUMAN] 
145.77 15.69 1 4 4 4 427 45.2 8.85 
D6RG15 Twinfilin-2 OS=Homo sapiens GN=TWF2 PE=2 SV=1 - [D6RG15_HUMAN] 141.51 18.11 2 3 3 4 254 28.9 6.13 
E7EUT5 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=2 SV=1 - [E7EUT5_HUMAN] 
136.83 16.54 3 3 3 4 260 27.9 6.95 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - 
[K2C78_HUMAN] 
135.59 8.27 1 4 4 4 520 56.8 6.02 
P08567 Pleckstrin OS=Homo sapiens GN=PLEK PE=1 SV=3 - [PLEK_HUMAN] 124.02 8.29 1 2 2 3 350 40.1 8.28 
H0YJC0 26S protease regulatory subunit 10B (Fragment) OS=Homo sapiens 
GN=PSMC6 PE=4 SV=1 - [H0YJC0_HUMAN] 
112.73 15.27 2 3 3 3 262 29.6 6.40 
P05089 Arginase-1 OS=Homo sapiens GN=ARG1 PE=1 SV=2 - [ARGI1_HUMAN] 112.65 9.32 2 2 2 2 322 34.7 7.21 
B4DNY3 Adenylyl cyclase-associated protein OS=Homo sapiens PE=2 SV=1 - 
[B4DNY3_HUMAN] 
107.25 10.97 7 3 3 3 401 43.7 8.54 
Q9Y371 Endophilin-B1 OS=Homo sapiens GN=SH3GLB1 PE=1 SV=1 - 
[SHLB1_HUMAN] 
104.86 7.67 2 2 2 2 365 40.8 6.04 
Q93020 GTP-binding regulatory protein Gi alpha-2 chain (Fragment) OS=Homo 
sapiens GN=WUGSC:H_LUCA16.1 PE=2 SV=2 - [Q93020_HUMAN] 
97.33 21.83 3 3 3 3 197 22.1 5.49 
P04040 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 - [CATA_HUMAN] 96.47 4.55 1 2 2 3 527 59.7 7.39 
B3KUZ8 Aspartate aminotransferase OS=Homo sapiens PE=2 SV=1 - 
[B3KUZ8_HUMAN] 
95.19 7.01 4 2 2 2 371 41.3 8.84 
A8K0T9 cDNA FLJ75422, highly similar to Homo sapiens capping protein (actin 
filament) muscle Z-line, alpha 1, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K0T9_HUMAN] 
93.54 9.09 2 2 2 2 286 32.9 5.69 
B4DLC0 Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=2 SV=1 - 
[B4DLC0_HUMAN] 
88.38 8.97 2 2 2 3 301 32.1 7.90 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=2 SV=1 - 
[Q9HB00_HUMAN] 
85.80 2.86 2 2 2 3 840 93.8 5.53 
E7DVW5 Fatty acid binding protein 5 (Psoriasis-associated) OS=Homo sapiens 
GN=FABP5 PE=2 SV=1 - [E7DVW5_HUMAN] 
79.22 13.33 1 2 2 2 135 15.2 7.01 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs MW [kDa] calc. pI 
B2RDE1 cDNA, FLJ96568, highly similar to Homo sapiens tropomyosin 3 (TPM3), mRNA 
OS=Homo sapiens PE=2 SV=1 - [B2RDE1_HUMAN] 
1835.02 62.10 1 13 22 65 248 29.0 4.75 
P67936 Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 PE=1 SV=3 - 
[TPM4_HUMAN] 
1196.13 54.03 1 11 19 44 248 28.5 4.69 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 
903.90 37.92 1 7 16 27 472 51.5 5.16 
Q5DT20 Hornerin OS=Homo sapiens GN=HRNR PE=2 SV=1 - [Q5DT20_HUMAN] 847.20 16.04 2 14 14 31 2850 282.2 10.02 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - 
[K1C16_HUMAN] 
830.51 35.52 1 9 16 27 473 51.2 5.05 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - 
[K2C6B_HUMAN] 
710.30 18.44 1 1 10 24 564 60.0 8.00 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens 
PE=2 SV=1 - [B4DRR0_HUMAN] 
514.37 22.43 3 2 11 18 535 57.8 8.00 
B7Z722 Tropomyosin 1 (Alpha), isoform CRA_i OS=Homo sapiens GN=TPM1 PE=2 SV=1 - 
[B7Z722_HUMAN] 
472.50 32.26 2 3 11 19 248 28.6 4.79 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 379.48 4.14 1 10 10 13 2871 331.6 6.81 
P62258 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 - [1433E_HUMAN] 310.99 47.45 1 8 10 12 255 29.2 4.74 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - 
[K1C17_HUMAN] 
300.68 24.07 1 2 10 10 432 48.1 5.02 
F5GWP8 Junction plakoglobin OS=Homo sapiens GN=JUP PE=2 SV=1 - [F5GWP8_HUMAN] 292.11 16.92 1 2 8 9 591 66.3 5.19 
B4DVQ0 cDNA FLJ58286, highly similar to Actin, cytoplasmic 2 OS=Homo sapiens PE=2 SV=1 
- [B4DVQ0_HUMAN] 
270.45 27.33 3 7 7 10 333 37.3 5.71 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 234.23 6.39 1 4 4 5 1049 113.7 5.03 
P00491 Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP PE=1 SV=2 - 
[PNPH_HUMAN] 
218.81 24.22 2 5 5 6 289 32.1 6.95 
Q53FB0 Chloride intracellular channel 1 variant (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q53FB0_HUMAN] 
200.54 39.83 2 5 5 6 241 27.0 5.17 
Q96C19 EF-hand domain-containing protein D2 OS=Homo sapiens GN=EFHD2 PE=1 SV=1 - 
[EFHD2_HUMAN] 
199.71 34.58 1 7 7 8 240 26.7 5.20 
Q06323 Proteasome activator complex subunit 1 OS=Homo sapiens GN=PSME1 PE=1 SV=1 - 
[PSME1_HUMAN] 
139.03 20.88 2 5 5 5 249 28.7 6.02 
Table A.3: FADD-protein interactions isolated from Mass spectrometry analysis for sample 3, THP-1 macrophages treated with 
200ng/ml CH11.  
D0PNI1 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta 
polypeptide OS=Homo sapiens GN=YWHAZ PE=2 SV=1 - [D0PNI1_HUMAN] 
120.89 20.00 1 2 4 4 245 27.7 4.79 
P24534 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 - 
[EF1B_HUMAN] 
117.30 12.44 1 2 2 2 225 24.7 4.67 
B4DQ50 cDNA FLJ56823, highly similar to Protein-glutamine gamma-glutamyltransferase E 
(EC 2.3.2.13) OS=Homo sapiens PE=2 SV=1 - [B4DQ50_HUMAN] 
96.66 6.00 1 2 2 2 533 58.8 7.15 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 91.06 22.73 2 2 2 3 110 11.3 6.54 
H0YMM1 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=2 SV=1 - 
[H0YMM1_HUMAN] 
85.34 16.11 7 2 2 2 149 16.4 5.91 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] 83.90 2.09 1 3 3 3 2391 247.9 8.31 
C9JZ20 Prohibitin (Fragment) OS=Homo sapiens GN=PHB PE=2 SV=1 - [C9JZ20_HUMAN] 79.74 10.95 8 2 2 2 201 22.3 5.96 
P04040 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 - [CATA_HUMAN] 74.48 6.83 1 2 2 2 527 59.7 7.39 
Q6ZNL4 FLJ00279 protein (Fragment) OS=Homo sapiens GN=FLJ00279 PE=2 SV=1 - 
[Q6ZNL4_HUMAN] 
72.29 4.26 3 2 2 2 563 65.7 8.85 
P29508-2 Isoform 2 of Serpin B3 n=1 Tax=Homo sapiens RepID=P29508-2 68.77 9.17 3 2 2 2 338 38.5 6.74 
B1AHF3 NADH-cytochrome b5 reductase 3 membrane-bound form (Fragment) OS=Homo 
sapiens GN=CYB5R3 PE=2 SV=1 - [B1AHF3_HUMAN] 
64.39 16.33 3 2 2 2 147 16.7 9.73 
P00918 Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 - [CAH2_HUMAN] 59.42 9.62 1 2 2 2 260 29.2 7.40 
Q15404-2 Isoform 2 of Ras suppressor protein 1 n=2 Tax=Homo sapiens RepID=Q15404-2 52.30 7.14 4 2 2 2 224 25.5 8.72 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs MW [kDa] calc. pI 
F8W1R7 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=2 SV=1 
- [F8W1R7_HUMAN] 
3092.29 57.93 9 9 9 92 145 16.3 4.65 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - 
[H6VRF8_HUMAN] 
3049.76 45.81 6 26 30 91 644 66.0 8.12 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 - [K1C10_HUMAN] 
1622.25 46.40 1 19 24 42 584 58.8 5.21 
B4DNE0 cDNA FLJ52573, highly similar to Elongation factor 1-alpha 1 
OS=Homo sapiens PE=2 SV=1 - [B4DNE0_HUMAN] 
1451.44 17.22 14 4 4 43 395 42.6 9.01 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3 - [K1C9_HUMAN] 
1332.51 43.82 1 19 19 39 623 62.0 5.24 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
842.03 43.04 1 14 21 25 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 - [K1C14_HUMAN] 
680.47 32.42 1 6 13 20 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 
SV=4 - [K1C16_HUMAN] 
610.11 32.35 1 7 14 20 473 51.2 5.05 
Q6KB66-2 Isoform 2 of Keratin, type II cytoskeletal 80 n=1 Tax=Homo sapiens 
RepID=Q6KB66-2 
546.55 7.82 3 2 3 14 422 47.2 5.30 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 - [K2C5_HUMAN] 
482.26 20.68 1 8 12 15 590 62.3 7.74 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A 
OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 
409.54 23.18 3 6 12 13 535 57.8 8.00 
A1A4E9 Keratin 13 OS=Homo sapiens GN=KRT13 PE=2 SV=1 - 
[A1A4E9_HUMAN] 
394.16 19.21 2 4 8 13 458 49.6 4.96 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - 
[DESP_HUMAN] 
343.90 4.11 1 10 10 12 2871 331.6 6.81 
P14923 Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 - 
[PLAK_HUMAN] 
287.68 9.93 1 6 6 7 745 81.7 6.14 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - 
[PROF1_HUMAN] 
260.85 47.14 1 5 5 7 140 15.0 8.27 
A4D1U3 Single-stranded DNA-binding protein OS=Homo sapiens GN=SSBP1 
PE=2 SV=1 - [A4D1U3_HUMAN] 
230.52 37.84 2 4 4 6 148 17.2 9.60 
Q5DT20 Hornerin OS=Homo sapiens GN=HRNR PE=2 SV=1 - 
[Q5DT20_HUMAN] 
211.01 8.49 2 5 5 6 2850 282.2 10.02 
Q6ZNL4 FLJ00279 protein (Fragment) OS=Homo sapiens GN=FLJ00279 PE=2 
SV=1 - [Q6ZNL4_HUMAN] 
196.58 6.22 3 3 3 5 563 65.7 8.85 
Q01546 Keratin, type II cytoskeletal 2 oral OS=Homo sapiens GN=KRT76 
PE=1 SV=2 - [K22O_HUMAN] 
194.23 7.68 1 2 5 6 638 65.8 8.12 
B4DVQ0 cDNA FLJ58286, highly similar to Actin, cytoplasmic 2 OS=Homo 
sapiens PE=2 SV=1 - [B4DVQ0_HUMAN] 
188.71 14.11 9 4 4 5 333 37.3 5.71 
Table A.4: FADD-protein interactions isolated from Mass spectrometry analysis for sample 4, THP-1 macrophages treated with 
200ng/ml CH11.  
UPI00017BDB3
D 
FabOX108 Light Chain Fragment n=1 Tax=Homo sapiens 
RepID=UPI00017BDB3D 
165.60 21.20 1 3 3 4 217 23.8 6.67 
O15511 Actin-related protein 2/3 complex subunit 5 OS=Homo sapiens 
GN=ARPC5 PE=1 SV=3 - [ARPC5_HUMAN] 
149.08 21.19 1 3 3 4 151 16.3 5.67 
B8ZZQ6 Thymosin alpha-1 OS=Homo sapiens GN=PTMA PE=4 SV=1 - 
[B8ZZQ6_HUMAN] 
142.71 26.17 7 3 3 3 107 11.8 3.81 
A3KPC7 Histone H2A OS=Homo sapiens GN=HIST1H2AH PE=2 SV=1 - 
[A3KPC7_HUMAN] 
137.16 27.34 11 3 3 8 128 13.9 10.89 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - 
[DSG1_HUMAN] 
131.84 4.29 1 3 3 3 1049 113.7 5.03 
E7DVW5 Fatty acid binding protein 5 (Psoriasis-associated) OS=Homo 
sapiens GN=FABP5 PE=2 SV=1 - [E7DVW5_HUMAN] 
110.32 20.00 1 3 3 4 135 15.2 7.01 
O75348 V-type proton ATPase subunit G 1 OS=Homo sapiens 
GN=ATP6V1G1 PE=1 SV=3 - [VATG1_HUMAN] 
103.17 22.03 1 2 2 2 118 13.7 8.79 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 101.70 20.00 2 2 2 3 110 11.3 6.54 
Q08188 Protein-glutamine gamma-glutamyltransferase E OS=Homo sapiens 
GN=TGM3 PE=1 SV=4 - [TGM3_HUMAN] 
101.39 3.90 1 2 2 3 693 76.6 5.86 
P30049 ATP synthase subunit delta, mitochondrial OS=Homo sapiens 
GN=ATP5D PE=1 SV=2 - [ATPD_HUMAN] 
84.62 13.69 1 2 2 2 168 17.5 5.49 
B4DRV9 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens 
PE=2 SV=1 - [B4DRV9_HUMAN] 
73.21 10.23 3 2 2 2 215 23.2 8.54 
P61956 Small ubiquitin-related modifier 2 OS=Homo sapiens GN=SUMO2 
PE=1 SV=3 - [SUMO2_HUMAN] 
72.69 18.95 4 2 2 2 95 10.9 5.50 
P31025 Lipocalin-1 OS=Homo sapiens GN=LCN1 PE=1 SV=1 - 
[LCN1_HUMAN] 
64.37 12.50 1 2 2 2 176 19.2 5.58 
P13073 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 
OS=Homo sapiens GN=COX4I1 PE=1 SV=1 - [COX41_HUMAN] 
64.28 13.02 1 2 2 2 169 19.6 9.51 
P62854 40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 
- [RS26_HUMAN] 
59.10 20.87 2 2 2 2 115 13.0 11.00 
